[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"endometrial-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:endometrial-carcinoma":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,24,0,[8,51,79,99,119,168,215,258,280,308,328,355,375,393,426,452,484,510,592,615,645,676,695,718],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":50},"100492351","early-phase-1-a-study-of-short-course-radiation-therapy-with-chemotherapy-in-people-with-endometrial-cancer-100492351",false,"NCT05691010","A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer","A Feasibility Study of Integrated Delivery of Hypofractionated Pelvic IMRT With Carboplatin and Paclitaxel in Stage III Copy-Number Low and Copy-Number High Subtypes of Endometrial Cancer","Inclusion Criteria:\n\n* Patients must have newly diagnosed endometrial carcinoma. The following histologic subtypes are eligible for inclusion: endometrioid, serous, clear cell, dedifferentiated\u002Fundifferentiated, mixed epithelial, adenocarcinoma not otherwise specified, and carcinosarcoma.\n* Surgery must have included a hysterectomy, bilateral salpingo-oophorectomy, and pelvic lymph node surgical assessment (sentinel lymph node mapping and\u002For sampling). Para-aortic lymph node surgical assessment is optional.\n* Patients must have FIGO (2009) stage IIIA or IIIC1 disease (as determined by surgical staging).\n* Patients must consent to testing with MSK-IMPACT part A and are encouraged to consent to both parts A and C.\n* Age ≥ 18 years.\n* Patients must have an Karnofsky Performance Status (KPS) ≥ 70 (or ECOG 0 or 1).\n* Neurologic function: Neuropathy (sensory and motor) grade ≤ 1.\n* No residual gross disease after surgery.\n* No prior radiation therapy or chemotherapy for treatment of endometrial cancer.\n* No active infection requiring antibiotics, except for uncomplicated urinary tract infection.\n* Patients must have adequate organ function, defined by the following laboratory results prior to first study treatment:\n\n  * Absolute neutrophil count (ANC) ≥ 1500\u002FmcL\n  * Platelet count ≥ 100,000\u002FmcL\n  * AST\u002FALT ≤ 3X upper limit of normal (ULN)\n  * Total bilirubin ≤ 1.5X ULN. Patients with known Gilbert's disease and a total bilirubin ≤ 3X ULN may be enrolled.\n  * Creatinine ≤ 1.5X ULN\n* Entry into study is limited to no more than 12 weeks from the date of surgery.\n* Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.\n* Patients of childbearing age will by definition have undergone hysterectomy and bilateral oophorectomy prior to study enrollment.\n* Participants must agree not to breastfeed during the study or for 150 days after the last dose of study treatment.\n\nExclusion Criteria:\n\n* Patients whose endometrial cancers harbor known pathogenic POLE mutations\n* Patients whose endometrial cancers are mismatch repair deficient, as determined by immunohistochemical staining for MLH1, PMS2, MSH2, and MSH6 and\u002For MSI-H\n* Active inflammatory bowel disease, such as Crohn's disease or ulcerative colitis.\n* History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator. This includes but is not limited to: uncontrolled ventricular arrhythmia, recent (within 90 days) myocardial infarction, chronic obstructive pulmonary disease, uncontrolled major seizure disorder, unstable spinal cord compression, and superior vena cava syndrome.\n* Patients unfit for pelvic radiation therapy due to the following:\n\n  * Has had radiation therapy encompassing \\>20% of the bone marrow within 2 weeks, or any radiation therapy within 1 week prior to day 1 of protocol therapy\n  * Patients with a history of pelvic radiation.\n  * Patients with a history or current diagnosis of a vesicovaginal, enterovaginal, or colovaginal fistula.\n  * Any hematological abnormality or disorder that would be a contraindication to radiation per the treating physician.","FEMALE","18 Years",{"count":19,"type":20},28,"ESTIMATED","INTERVENTIONAL",[23],"EARLY_PHASE1","The purpose of this study is to find out whether short-course radiation therapy (1 week instead of the usual 5 weeks) with chemotherapy (carboplatin and paclitaxel) is practical (feasible), meaning that most participants are able to complete the treatment schedule.",[26,27,28,29,30],"Endometrial Cancer","Stage III Endometrial Cancer","Stage III Endometrial Carcinoma","Endometrial Carcinoma","Endometrial Carcinoma Stage III",[32,33,34,35,36,37,38],"endometrial cancer","endometrial cancer stage III","endometrial carcinoma stage III","stage III endometrial cancer","stage III endometrial carcinoma","Memorial Sloan Kettering Cancer Center","22-405","RECRUITING","2026-06-24",{"date":42,"type":43},"2026-06-25","ACTUAL",{"date":45,"type":43},"2023-01-10",{"date":47,"type":20},"2027-01-10",{"name":37,"class":49},"OTHER",7,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":16,"minAge":58,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":21,"phases":61,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},"100644342","flyte-device-for-improving-urinary-incontinence-among-endometrial-and-cervical-cancer-survivors-who-have-undergone-radiation-therapy-100644342","NCT07662824","Flyte Device for Improving Urinary Incontinence Among Endometrial and Cervical Cancer Survivors Who Have Undergone Radiation Therapy","Flyte System Transvaginal Mechanotherapy for Urinary Incontinence in Endometrial and Cervical Cancer Survivors: A Pilot Study","Inclusion Criteria:\n\n* Female patients who have received conventionally fractioned adjuvant or primary pelvic radiation therapy for endometrial or cervical cancer ≥ 3 months prior to registration\n* Age ≥ 21 years at enrollment\n* English speaking\n* Demonstrates understanding of the study protocol and has signed the Informed Consent Form (ICF)\n* Has a clinical diagnosis of urinary incontinence (stress urinary incontinence \\[SUI\\], urge urinary incontinence \\[UUI\\], mixed) or overactive bladder (OAB)\n* Ability to contract the pelvic floor muscles (PFMs) without pain\n* Ability to tolerate size 6 vaginal dilator\n* Internet access\n* Access to an iOS or Android smartphone or tablet with capabilities to download and use the Flyte app\n* Willing and able to participate in follow-up\n\nExclusion Criteria:\n\n* Participation in another clinical study which may interfere with study requirements\n* Currently receiving active cancer directed therapy (i.e., cytotoxic chemotherapy) in post hysterectomy patients\n* Completion of radiation therapy or surgery within 3 months of enrollment\n* Life expectancy is less than six months in the opinion of the investigator\n* Inability to tolerate insertion of the intravaginal wand. This will be recorded to support the usability of Flyte secondary endpoint\n* Suspected vesicovaginal or colovaginal fistula\n* Physical limitations that impede the patient's ability to participate (e.g., ability to grasp the wand and insert it and ability to turn on the Flyte controller unit)\n* Acute infection or hematuria\n* Inability to contract the PFMs or pain with contraction, as confirmed with intravaginal exam\n* Impaired cognitive function or neurologic conditions","21 Years",{"count":60,"type":20},44,[62],"NA","This clinical trial studies how well and how easy it is to use a device called Flyte in improving problems with bladder control (urinary incontinence) among endometrial and cervical cancer survivors who have undergone radiation therapy. Urinary incontinence is common after pelvic radiation therapy and can affect daily life and well-being. Access to in-person pelvic floor physical therapy can be limited. The Flyte device is designed for in-home use to deliver a series of mechanical vibrations at a specific frequency while the pelvic floor muscles are contracting and relaxing (i.e., normal, guided Kegel exercises). This treatment is called mechanotherapy. The Flyte device may improve urinary incontinence symptoms, as well as overall quality of life among endometrial and cervical cancer survivors who have undergone radiation therapy.",[65,29,66,67],"Cervical Carcinoma","Overactive Bladder","Voiding Disorders","NOT_YET_RECRUITING","2026-06-22",{"date":71,"type":43},"2026-06-23",{"date":73,"type":20},"2026-08-13",{"date":75,"type":20},"2028-08-13",{"name":77,"class":49},"Mayo Clinic",1,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":94,"leadSponsor":96,"locationsCount":98},"100614436","gyn-aide-gynecologic-oncology-navigation-through-ai-driven-education-100614436","NCT07279571","GYN-AIDE: Gynecologic Oncology Navigation Through AI-Driven Education","AI-chatbot Evaluation (Aim 1):\n\nInclusion Criteria:\n\n* Patient of the LA General gynecologic oncology clinic\n* Age 18 years or older\n* Previously obtained the HPV vaccination (initial chatbot evaluation)\n* Eligible for HPV vaccination (pilot intervention; age \\\u003C46)\n* Willing and able to provide informed consent\n\nExclusion Criteria:\n\n* Patients who do not speak English or Spanish\n* Patients who do not provide informed consent\n\nHPV vaccination rate (Aim 2):\n\nInclusion Criteria:\n\n* Patient of the LA General gynecologic oncology clinic\n* Age 18 years or older\n* Obtained the HPV vaccine\n\nExclusion Criteria:\n\n* None",{"count":86,"type":20},48,"OBSERVATIONAL","This study seeks to understand how endometrial cancer patients get medical information about cancer care and their satisfaction with those health-seeking methods. It also assesses patient interest in using an artificial intelligence educational resource.",[29],"2026-06-12",{"date":92,"type":43},"2026-06-16",{"date":90,"type":43},{"date":95,"type":20},"2028-06-09",{"name":97,"class":49},"University of Southern California",2,{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":16,"minAge":105,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":108,"conditions":109,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":118},"100544209","non-invasive-identification-of-endometrial-cancerendometrial-atypical-hyperplasia-with-an-ai-based-classifier-applied-to-transvaginal-ultrasound-in-patients-with-post-menopausal-bleeding-100544209","NCT06365905","Non-Invasive Identification of Endometrial Cancer\u002FEndometrial Atypical Hyperplasia With an AI-Based Classifier Applied to Transvaginal Ultrasound in Patients With Post-Menopausal Bleeding","Inclusion Criteria:\n\n* Age ≥ 55 years\n* At least one episode of postmenopausal bleeding (PMB)\n* Endometrial biopsy available from at Mayo Clinic (MN, AZ, FL), Mayo Clinic Health System (MCHS), or an external institution\n* Acceptance to participate in the study\n\nExclusion Criteria:\n\n* Diagnostic tests performed more than 90 days apart\n* Physical impediment\u002Frefusal to undergo transvaginal ultrasound (TVUS)","55 Years",{"count":107,"type":20},300,"This study evaluates if AI can be used with transvaginal ultrasound images for early detection of endometrial cancer or premalignant lesions.",[29],"2026-06-08",{"date":112,"type":43},"2026-06-10",{"date":114,"type":43},"2024-03-27",{"date":116,"type":20},"2027-06-30",{"name":77,"class":49},3,{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":126,"minAge":17,"maxAge":4,"enrollmentInfo":127,"targetDuration":4,"studyType":21,"phases":129,"briefSummary":132,"conditions":133,"keywords":148,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":167},"100509886","phase-1-fog-001-in-locally-advanced-or-metastatic-solid-tumors-100509886","NCT05919264","FOG-001 in Locally Advanced or Metastatic Solid Tumors","A Phase 1\u002F2 Study of FOG-001 in Participants With Locally Advanced or Metastatic Solid Tumors","Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Adequate organ and marrow function.\n\nAdditional Inclusion Criteria for Dose Escalation Cohorts (Part 1a and Part 1g):\n\n* Diagnosis of treatment-refractory advanced\u002Fmetastatic solid tumor that is non-MSI-H or non-dMMR colorectal cancer (CRC) or any other solid tumor with documented WNT- pathway activating mutations (WPAMs).\n\nAdditional Inclusion Criteria for Dose Escalation Cohorts (Part 1b):\n\n* Diagnosis of treatment-refractory advanced\u002Fmetastatic non-MSI-H or non-dMMR CRC.\n* At least one lesion that is suitable for a core needle biopsy.\n\nAdditional Inclusion Criteria for Dose Escalation and Dose Expansion Cohorts (Part 1c and Part 2c):\n\n* Histologically, cytologically, or radiographically confirmed HCC with a documented WPAM (by local ctDNA or tumor NGS testing) in APC or CTNNB1\n\nAdditional Inclusion Criteria for Dose Escalation and Dose Expansion Cohorts (Part 1d, Part 1h, and Part 2d):\n\n* Desmoid tumor (aggressive fibromatosis)\n\nAdditional Inclusion Criteria for Dose Escalation and Dose Expansion Cohorts (Part 1f-1 and Part 2f-1) FOG-001 + FOLFOX + Bevacizumab:\n\n* Diagnosis of locally advanced or metastatic non-MSI-H or non-dMMR CRC\n* Participants with tumors known to be negative for APC LoF mutations or CTNNB1 GoF mutations (per NGS tests) are not eligible.\n* One dose of mFOLFOX6 with or without bevacizumab in the unresectable or metastatic setting prior to enrollment is allowed.\n\nAdditional Inclusion Criteria for Dose Escalation and Dose Expansion Cohorts (Part 1f-2 and Part 2f-2): FOG-001 + Nivolumab\n\n* Non-MSI-H or non-dMMR (by local testing) CRC with or without liver metastases.\n* MSI-H CRC or solid tumors that are WPAM and resistant to a-PD-1\u002FPD-L1\n* Participants with tumors known to be negative for APC LoF mutations or CTNNB1 GoF mutations (per NGS tests) are not eligible\n\nAdditional Inclusion Criteria for Dose Escalation and Dose Expansion Cohorts (Part 1f-3 and Part 2f-3): FOG-001 + Trifluridine\u002FTipiracil + Bevacizumab\n\n* Diagnosis of locally advanced or metastatic non-MSI-H or non-dMMR (by local testing) CRC\n* Participants with tumors known to be negative for APC LoF mutations or CTNNB1 GoF mutations (per NGS tests) are not eligible.\n\nAdditional Inclusion Criteria for Dose Expansion Cohort (Part 2a):\n\n* Diagnosis of locally advanced or metastatic non-MSI-H or non-dMMR (by local testing) CRC\n\nAdditional Inclusion Criteria for Dose Expansion Cohort (Part 2b):\n\n* Diagnosis of advanced or metastatic solid tumors with a documented WPAM (by local testing) or equivalent evidence\n\nExclusion Criteria:\n\n* Known history of bone metastasis. Bone metastasis are allowed for patients with mCRPC.\n* Evidence of vertebral compression fracture or non-traumatic bone fracture within the past 12 months and who are not receiving antiresorptive therapy.\n* Osteoporosis, which is defined as a T-score of ≤-2.5 at the lumbar spine (L1 - L4), left (or right) femoral neck or left (or right) total hip as determined by DXA scan.\n* Uncontrolled inflammatory bowel disease (i.e., ulcerative colitis or Crohn's disease)\n* Unstable\u002Finadequate cardiac function.\n* Has known meningeal carcinomatosis, leptomeningeal carcinomatosis, spinal cord compression, or symptomatic or unstable brain metastases.\n* Pregnant, lactating, or planning to become pregnant.","ALL",{"count":128,"type":20},595,[130,131],"PHASE1","PHASE2","The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors.",[134,135,136,137,138,139,140,141,142,143,144,29,145,146,147],"Cancer","Colorectal Cancer","Solid Tumor","Locally Advanced Solid Tumor","Metastatic Cancer","WNT Pathway","HCC","Desmoid","Microsatellite Stable Colorectal Cancer","Metastatic Castration-resistant Prostate Cancer","FAP","Prostate Cancer","Microsatellite Instability-High Colorectal Cancer","Adamantinomatous Craniopharyngioma",[134,136,137,138,149,150,151,141,152,153,154,155,156],"WNT Pathway Activating Mutation (WPAM)","Colorectal Cancer (CRC)","Microsatellite Stable (MSS)","Hepatocellular Carcinoma (HCC)","Adenomatous Polyposis Coli (APC)","β-catenin","Beta-catenin","CTNNB1","2026-05-26",{"date":159,"type":43},"2026-05-28",{"date":161,"type":43},"2023-05-23",{"date":163,"type":20},"2027-08-31",{"name":165,"class":166},"Parabilis Medicines, Inc.","INDUSTRY",33,{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":4,"eligibilityCriteria":174,"healthyVolunteers":11,"sex":126,"minAge":17,"maxAge":4,"enrollmentInfo":175,"targetDuration":4,"studyType":21,"phases":177,"briefSummary":178,"conditions":179,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":78},"100614857","phase-2-the-cancer-connected-access-and-remote-expertise-beyond-walls-program-to-provide-in-home-cancer-treatment-and-improve-treatment-satisfaction-in-cancer-patients-living-in-the-florida-panhandle-and-surrounding-areas-100614857","NCT07285044","The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas","Cancer CARE (Connected Access and Remote Expertise) Beyond Walls - Pilot, Phase 2 Clinical Trial to Evaluate Administration of Cancer-Directed Therapy in the Patient's Homes Versus in Clinic in the Florida Panhandle and Surrounding Areas","Inclusion Criteria:\n\n* Patient has had adequate tolerability of their clinical standard of care treatment, in the opinion of their treating physician, and no clinically significant drug-related reactions occurred prior to consent\n* Participant must be receiving a standard-of-care treatment regimen listed in this protocol that is being used in accordance with standard medical practice. Specifically, it must be either a) Food and Drug Administration (FDA)-approved for the participant's disease indication, or b) recommended in nationally recognized professional guidelines (e.g. National Comprehensive Cancer Network \\[NCCN\\], American Society of Clinical Oncology \\[ASCO\\], American Society of Hematology \\[ASH\\], etc.) as standard of care for the disease indication. Off-label use is permitted only if supported by such guidelines\n* A social stability screener, used per standard of care, indicates patient is appropriate to participate in the CCBW program\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, 2 or 3 at the discretion of the treating physician\n* Female or male patients age \\>= 18 years at the time of consent\n* Willing and able to comply with the study protocol in the investigator's judgement\n* Patients with histologically confirmed malignancy who are currently receiving treatment with one of the eligible treatment regimens. Patients with hepatocellular carcinoma (HCC) are eligible based on imaging diagnosis alone: histologic confirmation is not required.\n\n  * Note: patients diagnosed with any of the following disease types may receive any of the eligible regimens listed. Additionally, patients receiving hormonal or immunotherapy, such as nivolumab or pembrolizumab, may receive these infusions in home supplemental to any of the regimens identified. Co-administration with hormonal agents such as anti-androgens, poly(ADP-ribose) polymerase (PARP) inhibitors, oral gonadotrophin releasing hormone (GnRh) antagonists, estrogens, selective estrogen receptor modulators (SERMs), or aromatase inhibitors are allowed, however combinations of oral regimens only are not permitted. Patients may receive any combination of any listed medications or regimens\n  * Eligible disease cancer types:\n\n    * Amyloidosis\n    * Basal cell carcinoma\n    * Biliary\n    * Bladder\n    * Breast\n    * Cervical\n    * Colorectal\n    * Endometrial\n    * Fallopian tube\n    * Gastroesophageal\n    * Glioblastoma\n    * Head and neck\n    * Hepatocellular\n    * Hodgkin lymphoma\n    * Lung\n    * Mantle cell lymphoma\n    * Merkle cell carcinoma\n    * Multiple myeloma\n    * Melanoma\n    * Myelodysplastic syndrome\n    * Ovarian\n    * Pancreatic\n    * Peritoneal\n    * Prostate\n    * Renal cell carcinoma\n    * Squamous cell carcinoma\n    * Urothelial carcinoma\n  * Eligible regimens\n\n    * Atezolizumab +\u002F- bevacizumab\n    * Avelumab\n    * Bevacizumab\n    * Bortezomib\n    * Cemiplimab\n    * Daratumumab +\u002F- bortezomib\n    * Darbepoetin alpha\n    * Degarelix\n    * Denosumab (Xgeva)\n    * Durvalumab\n    * Fluorouracil +\u002F- bevacizumab\n    * Fulvestrant\n    * Goserelin\n    * Ipilimumab +\u002F- Nivolumab\n    * Lanreotide\n    * Leuprolide\n    * Nivolumab\n    * Nivolumab + relatlimab\n    * Octreotide\n    * Pembrolizumab\n    * Pertuzumab +\u002F- trastuzumab\n    * Trastuzumab +\u002F- pertuzumab\n    * Zoledronic acid (Zometa)\n* Willingness to follow birth control requirements for females and males of reproductive potential\n* Resides within the Florida Panhandle and surrounding area serviced by the at-home healthcare supplier utilized for the study and a paramedic network\n* Patient's residence has an existing Wi-Fi connection or can be connected using using a mobile Wi-Fi device provided as part of the program so as to enable a reliable connection with the remote CCBW Command Center at Mayo Clinic\n* Patients who, according to documentation from their treating provider, plan to continue the eligible treatment regimen they are currently prescribed for \\>= 12 weeks from the time of registration\n* Provide written informed consent\n* Ability to complete questionnaire(s) by themselves or with assistance\n* Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)\n\nExclusion Criteria:\n\n* Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens\n* Receiving any investigational agent which would be considered as a treatment for the primary neoplasm.\n\n  * Note: oral concomitant medications for oncologic indications will be maintained per standard of care treatment and not considered part of the trial. Any nononcologic medication, regardless of route of administration will be maintained per standard of care treatment and also not considered part of the trial; therefore, patients receiving oral anti-cancer or other medications per standard of care treatment in addition to any of the medications listed are considered eligible for this trial\n* Individuals who require continuous (24\u002F7) assistance with daily living and are unable to independently manage the technology required for study participation, unless a caregiver is available and willing to provide consistent support throughout the study\n* Current inpatient hospitalization (excluding admission to the Advanced Care at Home program)",{"count":176,"type":20},27,[131],"This phase II trial studies whether providing cancer treatment in the home is preferred over the traditional clinic setting and if it improves treatment satisfaction in cancer patients living in the Florida Panhandle and surrounding areas. Typically, drug-related cancer care is provided at a medical center which causes patients to have to spend considerable time away from their family, friends, and familiar surroundings. This may add to the physical, emotional, social, and financial burden for patients and their families during this difficult time in their lives. The Cancer Connected Access and Remote Expertise (CARE) Beyond Walls (CCBW) program uses a specialized care team trained to provide cancer treatment in the patient's home setting. It is designed to support remote connection between the home health team and providers and Mayo clinic. This may be preferred over the traditional clinic setting which may improve treatment satisfaction in cancer patients living in the Florida Panhandle and surrounding areas.",[180,181,182,183,184,65,185,29,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206],"Amyloidosis","Basal Cell Carcinoma","Biliary Tract Carcinoma","Bladder Carcinoma","Breast Carcinoma","Colorectal Carcinoma","Fallopian Tube Carcinoma","Gastroesophageal Junction Carcinoma","Glioblastoma","Head and Neck Carcinoma","Hematopoietic and Lymphatic System Neoplasm","Hepatocellular Carcinoma","Hodgkin Lymphoma","Lung Carcinoma","Malignant Solid Neoplasm","Mantle Cell Lymphoma","Melanoma","Merkel Cell Carcinoma","Multiple Myeloma","Myelodysplastic Syndrome","Ovarian Carcinoma","Pancreatic Carcinoma","Primary Peritoneal Carcinoma","Prostate Carcinoma","Renal Cell Carcinoma","Squamous Cell Carcinoma","Urothelial Carcinoma","2026-05-15",{"date":209,"type":43},"2026-05-18",{"date":211,"type":43},"2025-12-18",{"date":213,"type":20},"2026-12-18",{"name":77,"class":49},{"id":216,"slug":217,"hasResults":11,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":4,"eligibilityCriteria":221,"healthyVolunteers":11,"sex":126,"minAge":222,"maxAge":223,"enrollmentInfo":224,"targetDuration":4,"studyType":21,"phases":226,"briefSummary":227,"conditions":228,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":257},"100427831","phase-1-tegavivint-for-the-treatment-of-recurrent-or-refractory-solid-tumors-including-lymphomas-and-desmoid-tumors-100427831","NCT04851119","Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors","A Phase 1\u002F2 Study of Tegavivint (NSC#826393) in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors","Inclusion Criteria:\n\n* PART A: Patients must be \\>= 12 months and =\\\u003C 21 years of age at the time of study enrollment\n* PART B: Patients must be \\>= 12 months and =\\\u003C 30 years of age at the time of study enrollment\n* Patients with recurrent or refractory solid tumors including non-Hodgkin lymphoma and desmoid tumors are eligible. Patients must have had histologic verification of malignancy at original diagnosis or relapse\n* PART A: Patients with relapsed or refractory solid tumors, including patients with non-Hodgkin lymphoma and desmoid tumors\n* PART B: Patients with recurrent or refractory Ewing sarcoma, desmoid tumors, osteosarcoma, liver tumors (HCC and hepatoblastoma), Wilms tumor, and tumors with Wnt pathway aberrations. For the Wnt pathway aberrations cohort we will include the most common CTNNB1 mutations (S37F, S45F, T41A, S45P, S33C, S37C, D32Y, S33F, T41I, G34R, G34V, D32N, S33P, G34E, D32G) as well as any loss of function mutations in the APC, Axin2FBXW7, TCF7L2, and RNF43 genes or any gain-of-function mutations in the GSK3B, LRP6, and LGR5 genes. For patients without prior sequencing, immunohistochemistry (IHC), is required. IHC showing strong nuclear beta-catenin staining will be accepted for the following tumor types: colorectal carcinoma, melanoma, endometrial cancer, ovarian cancer, neuroblastoma, non-Hodgkin lymphoma, pancreatic ductal adenocarcinoma, and solid pseudopapillary tumor of the pancreas\n* PART A: Patients must have either measurable or evaluable disease. For desmoid tumors, the patient must have disease that the investigator deems unresectable or sufficiently morbid or potentially life-threatening that there is favorable risk\u002Fbenefit to the patient to participate in the trial\n* PART B: Patients must have measurable disease. For desmoid tumors, the patient must have measurable disease that the investigator deems unresectable or sufficiently morbid or potentially life-threatening that there is favorable risk\u002Fbenefit to the patient to participate in the trial\n* Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1 or 2. Use Karnofsky for patients \\> 16 years of age and Lansky for patients =\\\u003C 16 years of age\n* Patients must have fully recovered from the acute toxic effects of all prior anti-cancer therapy and must meet the following minimum duration from prior anti-cancer directed therapy prior to enrollment. If after the required timeframe, the numerical eligibility criteria are met, e.g., blood count criteria, the patient is considered to have recovered adequately.\n\n  * Cytotoxic chemotherapy or other anti-cancer agents known to be myelosuppressive\n\n    * Solid tumor patients: \\>= 21 days after the last dose of myelosuppressive chemotherapy (42 days if prior nitrosourea)\n    * Non-Hodgkin lymphoma patients\n\n      * A waiting period prior to enrollment is not required for patients receiving standard maintenance chemotherapy (i.e., corticosteroid, vincristine, thioguanine \\[6MP\\], and\u002For methotrexate)\n      * \\>= 14 days must have elapsed after the completion of other cytotoxic therapy, with the exception of hydroxyurea, for patients not receiving standard maintenance therapy\n      * NOTE: Cytoreduction with hydroxyurea must be discontinued \\>= 24 hours prior to the start of protocol therapy\n  * Anti-cancer agents not known to be myelosuppressive (e.g., not associated with reduced platelet or absolute neutrophil counts \\[ANC\\]): \\>= 7 days after the last dose of agent\n  * Antibodies: \\>= 21 days must have elapsed from infusion of last dose of antibody, and toxicity related to prior antibody therapy must be recovered to grade =\\\u003C 1\n  * Corticosteroids: If used to modify immune adverse events related to prior therapy, \\>= 14 days must have elapsed since last dose of corticosteroid\n  * Hematopoietic growth factors: \\>= 14 days after the last dose of a long-acting growth factor (e.g., pegfilgrastim) or 7 days for short acting growth factor. For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur\n  * Interleukins, interferons and cytokines (other than hematopoietic growth factors): \\>= 21 days after the completion of interleukins, interferon or cytokines (other than hematopoietic growth factors)\n  * Stem cell Infusions (with or without total-body irradiation \\[TBI\\]):\n\n    * Allogeneic (non-autologous) bone marrow or stem cell transplant, or any stem cell infusion including donor lymphocyte infusion (DLI) or boost infusion: \\>= 84 days after infusion and no evidence of graft versus host disease (GVHD)\n    * Autologous stem cell infusion including boost infusion: \\>= 42 days.\n  * Cellular therapy: \\>= 42 days after the completion of any type of cellular therapy (e.g., modified T cells, natural killer \\[NK\\] cells, dendritic cells, etc.).\n  * External beam radiation therapy (XRT)\u002Fexternal beam irradiation including protons: \\>= 14 days after local XRT; \\>= 150 days after TBI, craniospinal XRT or if radiation to \\>= 50% of the pelvis; \\>= 42 days if other substantial bone marrow (BM) radiation\n  * Radiopharmaceutical therapy (e.g., radiolabeled antibody, iobenguane I-131 \\[131I MIBG\\]): \\>= 42 days after systemically administered radiopharmaceutical therapy\n  * Patients must not have received prior exposure to tegavivint\n* PATIENTS WITH SOLID TUMORS WITHOUT KNOWN BONE MARROW INVOLVEMENT: Peripheral absolute neutrophil count (ANC) \\>= 1000\u002FuL (within 7 days prior to enrollment)\n* PATIENTS WITH SOLID TUMORS WITHOUT KNOWN BONE MARROW INVOLVEMENT: Platelet count \\>= 100,000\u002FuL (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment) (within 7 days prior to enrollment)\n* PATIENTS WITH SOLID TUMORS WITHOUT KNOWN BONE MARROW INVOLVEMENT: Hemoglobin \\>= 8.0 g\u002FdL at baseline (may receive red blood cell \\[RBC\\] transfusions) (within 7 days prior to enrollment)\n* Patients with known bone marrow metastatic disease will be eligible for study provided they meet blood counts (may receive transfusions provided they are not known to be refractory to red cell or platelet transfusions). These patients will not be evaluable for hematologic toxicity. At least 5 of every cohort of 6 patients must be evaluable for hematologic toxicity for the dose-escalation part of the study. If dose-limiting hematologic toxicity is observed, all subsequent patients enrolled on Part A must be evaluable for hematologic toxicity\n* Creatinine clearance or radioisotope glomerular filtration rate (GFR) \\>= 70 mL\u002Fmin\u002F1.73 m\\^2 or a creatinine based on age\u002Fgender as follows (within 7 days prior to enrollment):\n\n  * Age; maximum serum creatinine\n  * Age 1 to \\\u003C 2 years; 0.6 mg\u002FdL (male); 0.6 mg\u002FdL (female)\n  * Age 2 to \\\u003C 6 years; 0.8 mg\u002FdL (male); 0.8 mg\u002FdL (female)\n  * Age 6 to \\\u003C 10 years; 1 mg\u002FdL (male); 1 mg\u002FdL (female)\n  * Age 10 to \\\u003C 13 years; 1.2 mg\u002FdL (male); 1.2 mg\u002FdL (female)\n  * Age 13 to \\\u003C 16 years; 1.5 mg\u002FdL (male); 1.4 mg\u002FdL (female)\n  * Age \\>= 16 years; 1.7 mg\u002FdL (male); 1.4 mg\u002FdL (female)\n* PATIENTS WITH SOLID TUMORS: Bilirubin (sum of conjugated + unconjugated or total) =\\\u003C 1.5 x upper limit of normal (ULN) for age (within 7 days prior to enrollment)\n* PATIENTS WITH SOLID TUMORS: Serum glutamic pyruvic transaminase (SGPT) (alanine aminotransferase \\[ALT\\]) =\\\u003C 135 U\u002FL. For the purpose of this study, the ULN for SGPT is 45 U\u002FL (within 7 days prior to enrollment)\n* PATIENTS WITH SOLID TUMORS: Albumin \\>= 2 g\u002FdL (within 7 days prior to enrollment)\n\nExclusion Criteria:\n\n* Pregnant or breast-feeding women will not be entered on this study because there is yet no available information regarding human fetal or teratogenic toxicities. Pregnancy tests must be obtained in girls who are post-menarchal. Males or females of reproductive potential may not participate unless they have agreed to use two effective methods of birth control, including a medically accepted barrier or contraceptive method (e.g., male or female condom) for the duration of the study. Abstinence is an acceptable method of birth control\n* Patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible. If used to modify immune adverse events related to prior therapy, \\>= 14 days must have elapsed since last dose of corticosteroid\n* Patients who are currently receiving another investigational drug are not eligible\n* Patients who are currently receiving other anti-cancer agents are not eligible\n* Patients who are receiving cyclosporine, tacrolimus or other agents to prevent graft-versus-host disease post bone marrow transplant are not eligible for this trial\n* Patients who are currently receiving drugs that are strong inducers or inhibitors of CYP3A4 are not eligible. Strong inducers or inhibitors of CYP3A4 should be avoided from 14 days prior to the 1st dose of tegavivint to the end of the study\n* Patients who have received bisphosphonates within 4 weeks prior to study enrollment will be excluded\n* Patients who have received denosumab within 180 days prior to study enrollment will be excluded\n* Patients with primary brain tumors are ineligible\n* Patients with known central nervous system (CNS) metastasis, except for craniopharyngeal tumors, will be excluded\n* Patients with a known metabolic bone disease (ex: hyperparathyroidism, Paget's disease, osteomalacia) are not eligible\n* Patients with a disorder associated with abnormal bone metabolism will be excluded\n* Patients with grade \\>= 2 hypocalcemia that is not corrected with oral calcium supplementation will be excluded\n* Patients with vitamin D \\\u003C 20 ng\u002FmL will require supplementation, or will otherwise be excluded. Patients must agree to take vitamin D +\u002F- calcium supplements (if necessary) according to institutional or published guidelines. Additional calcium supplementation is not required if adequate dietary intake can be ascertained\n* Patients with pre-existing grade 3 osteoporosis are excluded\n* Patients who have an uncontrolled infection are not eligible\n* Patients who have received a prior solid organ transplantation are not eligible\n* Patients who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study are not eligible","12 Months","30 Years",{"count":225,"type":20},147,[130,131],"This phase I\u002FII trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interferes with the binding of beta-catenin to TBL1, which may help stop the growth of tumor cells by blocking the signals passed from one molecule to another inside a cell that tell a cell to grow.",[185,29,196,229,200,230,231,232,233,234,235,236,237,238,239,240,241,242,243,244,245,246],"Neuroblastoma","Pancreatic Ductal Adenocarcinoma","Recurrent Desmoid Fibromatosis","Recurrent Ewing Sarcoma","Recurrent Hepatoblastoma","Recurrent Hepatocellular Carcinoma","Recurrent Malignant Solid Neoplasm","Recurrent Non-Hodgkin Lymphoma","Recurrent Osteosarcoma","Refractory Desmoid Fibromatosis","Refractory Ewing Sarcoma","Refractory Hepatoblastoma","Refractory Hepatocellular Carcinoma","Refractory Malignant Solid Neoplasm","Refractory Non-Hodgkin Lymphoma","Refractory Osteosarcoma","Solid Pseudopapillary Neoplasm of the Pancreas","Wilms Tumor","2026-05-01",{"date":249,"type":43},"2026-05-05",{"date":251,"type":43},"2021-11-08",{"date":253,"type":20},"2028-06-30",{"name":255,"class":256},"Children's Oncology Group","NETWORK",21,{"id":259,"slug":260,"hasResults":11,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":4,"eligibilityCriteria":264,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":265,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":267,"conditions":268,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":78},"100597709","molecular-and-ctdna-characterization-of-high-risk-endometrial-cancer-100597709","NCT07062016","Molecular and ctDNA Characterization of High-Risk Endometrial Cancer","MC230601 Molecular and ctDNA Characterization of High-Risk Endometrial Cancer","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Planned complete surgical staging at Mayo Clinic. Complete surgical staging includes at least total hysterectomy, bilateral salpingo-oophorectomy and lymph node assessment. Sentinel node mapping meets the criteria for lymph node assessment. Peritoneal cytology is recommended. Additional staging procedures such as pelvic and para-aortic nodal evaluation, omental biopsy or omentectomy, may also be utilized for staging in patients based on the clinical situation and at the surgeon's discretion\n* At least one preoperative or postoperative feature of aggressive disease \\[International Federation of Gynecology and Obstetrics (FIGO) staging used throughout this protocol\\]\n\n  * Preoperatively:\n\n    * Biopsy with grade 3 endometrioid endometrial cancer (EC) or non-endometrioid EC\n    * Patients with FIGO grade 1-2 EC with evidence of extrauterine disease on imaging (CT, MRI, or PET)\n  * Postoperatively:\n\n    * Endometrial cancer (FIGO) with one or more established risk factors:\n\n      * Non-endometrioid histology\n\n        * Grade 3\n      * Lymphovascular space invasion (LVSI), ≥ 50% of myometrial invasion, presence of isolated tumor cells (ITC) in a sentinel lymph node OR\n      * Stage II to IV (FIGO) EC\n* Provide written informed consent\n* Willingness to provide mandatory blood specimens for correlative research\n* Willingness to provide mandatory tissue specimens for correlative research\n* Willingness to return to registering site for clinical follow-up\n\nExclusion Criteria:\n\n* Patient receiving or who has received neoadjuvant chemotherapy\n* Pre-operative pregnancy",{"count":266,"type":20},100,"This study seeks to better understand the recurrence of high-risk endometrial cancer. It will collect information about cancer genetics to find out various hereditary or cancer specific genetic variants that may have a role in diagnosis or management and prognosis of cancer. It also seeks to develop a genetic results and medical record databank for future studies.",[29,269,270,27,271],"Endometrial High Grade Endometrioid Adenocarcinoma","Stage II Endometrial Cancer","Stage IV Endometrial Cancer","2026-04-09",{"date":274,"type":43},"2026-04-13",{"date":276,"type":43},"2025-10-01",{"date":278,"type":20},"2028-10-31",{"name":77,"class":49},{"id":281,"slug":282,"hasResults":11,"nctId":283,"briefTitle":284,"officialTitle":284,"acronym":4,"eligibilityCriteria":285,"healthyVolunteers":11,"sex":126,"minAge":17,"maxAge":286,"enrollmentInfo":287,"targetDuration":4,"studyType":21,"phases":289,"briefSummary":290,"conditions":291,"keywords":294,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":299,"lastUpdatePostDateStruct":300,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":78},"100535566","phase-1-pembrolizumab-lenvatinib-and-il-15-superagonist-n-803-in-combination-with-her2-targeting-autologous-dendritic-cell-adher2dc-vaccine-in-participants-with-advanced-or-metastatic-endometrial-cancer-100535566","NCT06253494","Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer","* INCLUSION CRITERIA:\n* Histologically confirmed endometrial cancer.\n* Radiographically confirmed metastatic or locally advanced disease.\n* Evaluable (measurable or non-measurable) disease, per RECIST 1.1.\n* HER2 IHC 1+, 2+ or 3+ tumor confirmed by PATHWAY HER2 (4B5) test. NOTE: The HER2 status in participants who had prior anti-HER2 therapy should be confirmed in the tumor tissue obtained after completing the anti-HER2 therapy.\n* Participants must have received and progressed after at least one (1) line of systemic therapy for endometrial cancer.\n* Age \\>=18 years.\n* ECOG performance status \\\u003C=2.\n* Participants must have available tumor tissue or be willing to undergo a mandatory research biopsy. NOTE: Samples must be collected after HER2 directed therapy if the participant had anti-HER2 therapy.\n* Participants must have adequate organ and marrow function as defined below:\n\n  * Absolute neutrophil count (ANC) \\> 1,000\u002Fmicroliter\n  * Platelets \\> 100,000\u002Fmicroliter\n  * Hemoglobin (Hgb) \\> 9 g\u002FdL (any number of transfusions within 60 days before apheresis is allowed)\n  * Total bilirubin \\\u003C=1.5 X upper limit of normal (ULN). NOTE: In participants with Gilbert s Syndrome or known liver metastasis, total bilirubin \\\u003C=3.0 X ULN is allowed\n  * Aspartate aminotransferase (AST) \u002F Alanine aminotransferase (ALT) \\\u003C=3.0 X ULN. NOTE: AST\u002FALT \\\u003C=5.0 X ULN is allowed in participants with known liver metastasis\n  * An estimated creatinine clearance (CrCl) \\\u003C=1.5 X ULN OR \\>30 mL\u002Fmin\u002F1.73 m2 for participants with creatinine levels \\>1.5 X ULN (calculated creatinine clearance (CrCl) (eGFR may also be used in place of CrCl)\n  * Dip stick urine protein \\\u003C 3 or urine protein \\\u003C 1 gram (g)\u002F24 hour if dip stick urine is \\>= 3+\n* Hepatitis B virus (HBV)-infected participants can be enrolled if HBV DNA is undetectable. Hepatitis C virus (HCV)-infected participants can be enrolled if HCV RNA level is undetectable.\n* Participants with previously treated non-active brain metastases or central nervous system metastases more than 28 days from definitive radiotherapy or surgery are eligible.\n* Individuals of child-bearing potential (IOCBP) must agree to use highly effective contraception (hormonal, intrauterine device (IUD), tube ligation, a partner has had the previous vasectomy, abstinence) at the time of study entry, for the duration of study treatment, and up to 6 months after the last dose of the study drug(s).\n* Nursing participants must be willing to discontinue nursing from study treatment initiation through 6 months after the last dose of the study drug(s).\n* Participants must be able to understand and be willing to sign a written informed consent document.\n\nEXCLUSION CRITERIA\n\n* Administration of any standard of care or investigational checkpoint inhibitors (e.g., anti-CTLA, anti-PD-1, anti-PD-L1, anti-TIGIT, anti-TIM3, or anti-LAG3 antibodies or small molecules) within 6 months prior to apheresis.\n* History of grade 3 or 4 immune related adverse events from the use of immune checkpoint inhibitors.\n* History of Lenvatinib use\n* History of severe immediate hypersensitivity reaction to compounds similar to study drugs or their components (e.g., monoclonal antibody preparations).\n* Surgery to abdomen\u002Fpelvis\u002Fchest within 3 months prior to apheresis.\n* Other malignancies diagnosed within 24 months prior to apheresis. NOTE: Participants who completed treatment for in-situ carcinomas (e.g., breast, cervix, bladder), or basal or squamous cell carcinoma of the skin are eligible if no ongoing treatment is needed per Standard of Care.\n* Arterial or venous thromboembolism within 6 months prior to apheresis.\n* History of cerebrovascular accident or stroke (transient ischemic attack, hemorrhagic or ischemic) within 6 months prior to apheresis.\n* Functional or objective cardiac dysfunction: New York Heart Association (NYHA) Functional Capacity III or IV or Objective Assessment C or D.\n* Fridericia's corrected QT interval (QTcF) \\>= 480 msec or evidence of third-degree AV block on screening electrocardiogram (ECG).\n* Ejection fraction by screening echocardiogram \\\u003C 50 percent.\n* Participants requiring therapeutic anticoagulation regimen(s) (e.g., warfarin, rivaroxaban, apixaban, dabigatran, edoxaban, low molecular weight heparin \\[e.g., enoxaparin, dalteparin, tinzaparin\\], heparin, fondaparinux).\n* History of gastrointestinal or non-gastrointestinal fistula \\>= Grade 3 (CTCAE v.5.0).\n* Radiographic evidence of major blood vessel invasion\u002Finfiltration.\n* History of hemoptysis or tumor bleeding within 1 month prior to apheresis.\n* Current gastrointestinal malabsorption, gastrointestinal anastomosis, or any other condition that might affect the absorption of lenvatinib.\n* Any form of primary immunodeficiency.\n* Participants with active autoimmune disease or a history of autoimmune disease, which require immune suppressive treatment such as systemic corticosteroids or other systemic immune suppressants (e.g., methotrexate, cyclosporine, and biologics). NOTE: Participants with vitiligo, endocrine deficiencies on replacement dose are eligible.\n* Systemic corticosteroid therapy of higher than a physiologic dose (the equivalent of prednisone 10 mg\u002Fday) within 14 days prior to apheresis. NOTE: Any topical steroid medications (e.g., corticosteroid creams, ointments, and eye drops) are allowed.\n* Solid organ or allogeneic hematopoietic stem cell transplant recipients.\n* Human immunodeficiency virus (HIV)-positive participants.\n* Pregnancy (confirmed with beta-Human chorionic gonadotropin (HCG) serum or urine pregnancy test performed in IOCBP at screening).\n* Uncontrolled intercurrent illness or situation that would limit compliance with study requirements.","120 Years",{"count":288,"type":20},60,[130,131],"Background:\n\nEndometrial cancer (EC) of the uterus is becoming more common in the US. Sometimes EC often has increased levels of a protein called HER2. Cancers with HER2 tend to be more aggressive and have poorer outcomes.\n\nObjective:\n\nTo test 2 study drugs-a vaccine that targets HER2 (AdHER2DC) plus a drug that supercharges immune cells that kill tumor cells (N-803)-combined with 2 FDA-approved cancer treatment drugs in people with EC.\n\nEligibility:\n\nAdults aged 18 and older with HER2-positive EC that returned or got worse after treatment.\n\nDesign:\n\nAdHER2DC vaccine is made from each participant s own blood. Participants will undergo apheresis: Blood is removed from the body through a tube attached to a needle. The blood passes through a machine that separates out the target cells. The remaining blood is returned to the body through a second needle. A special catheter may be needed.\n\nThe first treatment cycle is 28 days; each cycle after that will be 21 days.\n\nAll participants will get the 2 approved drugs and the vaccine. One drug is a tablet taken by mouth once a day, every day. The other drug is given through a tube attached to a needle inserted into a vein.\n\nThe vaccine is injected under the skin. Participants will receive the vaccine on day 1 of cycles 1, 2, and 3. Additional doses up to 3 doses will be give if possible.\n\nSome participants will receive N-803. This drug is injected under the skin of the abdomen on day 1 of each cycle.\n\nTreatment may last up to 1 year. Follow-up visits will continue up to 2 more years.",[26,292,293,29],"Cancer of Endometrium","Carcinoma of Endometrium",[295,296,297,298],"Cancer Vaccine","Combination of anti-cancer drugs","Immunotherapy","HER2 Positive Cancer","2026-04-08",{"date":272,"type":43},{"date":302,"type":43},"2024-05-14",{"date":304,"type":20},"2028-12-31",{"name":306,"class":307},"National Cancer Institute (NCI)","NIH",{"id":309,"slug":310,"hasResults":11,"nctId":311,"briefTitle":312,"officialTitle":312,"acronym":4,"eligibilityCriteria":313,"healthyVolunteers":314,"sex":16,"minAge":315,"maxAge":4,"enrollmentInfo":316,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":318,"conditions":319,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":320,"lastUpdatePostDateStruct":321,"startDateStruct":323,"completionDateStruct":325,"leadSponsor":327,"locationsCount":78},"100633473","acceptability-of-testing-dna-markers-in-vaginal-fluid-for-the-detection-of-endometrial-cancer-100633473","NCT07527143","Acceptability of Testing DNA Markers in Vaginal Fluid for the Detection of Endometrial Cancer","Inclusion Criteria:\n\n* Self-identified Black individuals ≥ 45 years with an intact uterus\n* Assigned female sex at birth\n* Willing to participate in a 30-minute virtual interview\n\nExclusion Criteria:\n\n* Previous or current diagnosis of endometrial cancer",true,"45 Years",{"count":317,"type":20},25,"This study evaluates how women feel about using DNA from a vaginal fluid collection for early detection of endometrial cancer.",[29],"2026-04-07",{"date":322,"type":43},"2026-04-14",{"date":324,"type":20},"2026-04-06",{"date":326,"type":20},"2027-04-06",{"name":77,"class":49},{"id":329,"slug":330,"hasResults":11,"nctId":331,"briefTitle":332,"officialTitle":333,"acronym":4,"eligibilityCriteria":334,"healthyVolunteers":11,"sex":126,"minAge":17,"maxAge":4,"enrollmentInfo":335,"targetDuration":4,"studyType":21,"phases":337,"briefSummary":338,"conditions":339,"keywords":344,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":347,"startDateStruct":348,"completionDateStruct":350,"leadSponsor":352,"locationsCount":354},"100609555","phase-1-ft836-with-or-without-chemotherapy-andor-monoclonal-antibodies-in-participants-with-advanced-solid-tumors-100609555","NCT07216105","FT836 With or Without Chemotherapy and\u002For Monoclonal Antibodies, in Participants With Advanced Solid Tumors","A Phase 1, Open-Label Study of FT836, an Off-the-Shelf CAR T-Cell Therapy, With or Without Chemotherapy and\u002For Monoclonal Antibodies, in Participants With Advanced Solid Tumors","Inclusion Criteria:\n\n* For all regimens, disease that is not amenable to curative therapy and that has relapsed or progressed following at least one line of prior systemic therapy.\n* Evidence of adequate organ function as determined by all of the following:\n\n  * Absolute neutrophil count (ANC) \\>1000\u002FµL without growth factor support within 7 days prior to start of first study intervention\n  * Platelet count ≥75,000\u002FµL without transfusion support within 14 days prior to start of first study intervention\n  * Estimated creatinine clearance ≥50 mL\u002Fminute by Cockcroft-Gault method or other standard institutional method\n  * Total bilirubin ≤1.5 × upper limit of normal (ULN); for participants with documented Gilbert syndrome, total bilirubin must be ≤3 ×ULN\n  * Aspartate transaminase (AST) ≤3 × ULN or alanine transaminase (ALT) ≤3 × ULN; in participants with documented liver metastases, AST or ALT ≤5 × ULN\n  * Alkaline phosphatase (ALP) ≤2.5 × ULN; in participants with documented liver or bone metastases, ALP ≤5 × ULN\n  * Oxygen saturation \\>90% on room air\n* Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1.\n* Presence of measurable disease by RECIST, v1.1 assessed within 28 days prior to start of first study intervention.\n* Presence of baseline safely accessible lesions of adequate size for on-treatment biopsies (exceptions for lesion size may be granted with medical monitor approval) and participant willingness to undergo protocol prescribed on-treatment biopsies.\n\nExclusion Criteria:\n\n* Clinically significant cardiovascular disease including any of the following: uncontrolled\u002F unstable cardiac arrhythmias, myocardial infarction within 6 months prior to start of first study intervention, unstable angina or congestive heart failure of New York Heart Association (NYHA) Grade 2 or higher, or cardiac ejection fraction \\\u003C50%.\n* Receipt of any biological therapy, chemotherapy, investigational therapy, or radiation therapy within 2 weeks or five half-lives prior to start of fifirst study intervention, whichever is shorter.\n* Known active central nervous system (CNS) involvement by malignancy. Participants with prior CNS involvement from their malignancy must have completed effective treatment of their CNS disease with no symptoms of disease in the absence of steroid treatment and at least stable findings on relevant CNS imaging and no evidence of leptomeningeal disease for at least 4 weeks prior to study enrollment.\n* Non-malignant CNS disease such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease or receipt of medications for these conditions within 6 months prior to study enrollment.\n* Currently receiving or likely to require systemic immunosuppressive therapy (e.g., prednisone ≥5 mg daily) for any reason from start of first study intervention to Day 29 with the exception of corticosteroids as a premedication for chemotherapy side effects per institutional standard of care or as mandated by the protocol.\n* Any history of Grade ≥3 immune-related AE or Grade ≥2 eye toxicity attributed to prior cancer immunotherapy, other than endocrinopathy managed with replacement therapy or asymptomatic elevation of serum amylase or lipase.\n* Grade ≥2 peripheral neuropathy limiting instrumental activities of daily living.",{"count":336,"type":20},113,[130],"This is a phase 1 study of FT836 administered in participants with advanced solid tumors. The primary objectives of the study are to evaluate the safety and tolerability of FT836 with or without paclitaxel and\u002For trastuzumab or cetuximab, and to determine the recommended phase 2 dose (RP2D) of FT836 in combination with trastuzumab or cetuximab; each objective will be assessed with or without paclitaxel chemotherapy.",[340,135,341,342,29,343],"Non-Small Cell Lung Cancer","Breast Cancer","Ovarian Cancer","Head and Neck Squamous Cell Carcinoma",[345],"HNSCC, NSCLC, CRC","2026-04-03",{"date":320,"type":43},{"date":349,"type":43},"2025-11-04",{"date":351,"type":20},"2030-01",{"name":353,"class":166},"Fate Therapeutics",5,{"id":356,"slug":357,"hasResults":11,"nctId":358,"briefTitle":359,"officialTitle":360,"acronym":4,"eligibilityCriteria":361,"healthyVolunteers":314,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":362,"targetDuration":4,"studyType":21,"phases":363,"briefSummary":365,"conditions":366,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":368,"startDateStruct":370,"completionDateStruct":372,"leadSponsor":374,"locationsCount":78},"100614588","phase-4-low-dose-aspirin-to-lower-inflammation-and-prevent-endometrial-cancer-in-postmenopausal-women-with-non-atrophic-endometrial-changes-and-pain-100614588","NCT07281547","Low Dose Aspirin to Lower Inflammation and Prevent Endometrial Cancer in Postmenopausal Women With Non-atrophic Endometrial Changes and Pain","Mechanistic Randomized Controlled Feasibility Trial of Aspirin on Endometrium and Inflammatory Metabolites in Postmenopausal Women With Non-Atrophic Endometrial Changes","Inclusion Criteria:\n\n* PRE-REGISTRATION: Postmenopausal women\n* PRE-REGISTRATION: Transvaginal ultrasound\n* PRE-REGISTRATION: Scheduled endometrial biopsy\n* PRE-REGISTRATION: Provide risk factor survey\n* REGISTRATION: Postmenopausal (defined clinically by no period for over 1 year or postmenopausal follicle-stimulating hormone \\[FSH\\], estradiol, or anti-Mullerian hormone \\[AMH\\] levels due to natural, medical, or surgical causes)\n* REGISTRATION: Have pain (an indicator of inflammation) and other findings warranting endometrial sampling (postmenopausal bleeding \\[PMB\\], incidentally noted thickened endometrium \\> 4mm on ultrasound, obesity, fibroids)\n* REGISTRATION: Capable of providing informed consent\n* REGISTRATION: Understands English or Spanish language for consent and questionnaires\n* REGISTRATION: Ability to complete questionnaire(s) by themselves or with assistance\n* REGISTRATION: Willingness to provide mandatory blood specimens for correlative research\n* REGISTRATION: Willingness to provide mandatory tissue specimens for correlative research\n* REGISTRATION: Willingness to provide mandatory urine sample for correlative research\n\nExclusion Criteria:\n\n* PRE-REGISTRATION: Not postmenopausal person born with uterus\n* PRE-REGISTRATION: Atrophic endometrium\n* PRE-REGISTRATION: No uterus\n* PRE-REGISTRATION: Malignancy found\n* REGISTRATION: Patients with previous hysterectomy (removal of the uterus)\n* REGISTRATION: Atrophic endometrium on endometrial sampling performed clinically\n* REGISTRATION: Patients from outside the Mayo Clinic Comprehensive Cancer Center (MCCCC) area\n* REGISTRATION: Clinically contraindicated to discontinue use of anticoagulation other than aspirin\n* REGISTRATION: Contraindication to use of nonsteroidal anti-inflammatory drugs (NSAIDs) or previous adverse reaction or intolerance to NSAIDs\n* REGISTRATION: History of uterine, cervical, or ovarian cancers or precancers (endometrial hyperplasia, cervical dysplasia, fallopian tube intraepithelial carcinoma)",{"count":317,"type":20},[364],"PHASE4","This phase IV trial studies whether low dose aspirin can be used to lower inflammation and prevent endometrial cancer in postmenopausal women with changes in the endometrial tissue that are not related to thinning (non-atrophic endometrial changes) and pain. As people age, there is an accumulation of fats, cell death, and inflammation, which causes a surge of pro-cancer-causing events. It is thought that there are several factors involved in the development of endometrial cancer, but that managing the inflammation may address the root cause. Low dose aspirin is aspirin that contains a lower dose than a standard adult tablet. Aspirin is a drug that reduces pain, fever, inflammation, and blood clotting. Aspirin belongs to the family of drugs called nonsteroidal anti-inflammatory agents. It is also being studied in cancer prevention. Giving low dose aspirin may be an effective way to lower inflammation and prevent endometrial cancer in postmenopausal women with non-atrophic endometrial changes and pain.",[29],"2026-02-16",{"date":369,"type":43},"2026-02-18",{"date":371,"type":20},"2026-08-12",{"date":373,"type":20},"2027-06-11",{"name":77,"class":49},{"id":376,"slug":377,"hasResults":11,"nctId":378,"briefTitle":379,"officialTitle":380,"acronym":4,"eligibilityCriteria":381,"healthyVolunteers":314,"sex":126,"minAge":17,"maxAge":4,"enrollmentInfo":382,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":383,"conditions":384,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":385,"lastUpdatePostDateStruct":386,"startDateStruct":388,"completionDateStruct":390,"leadSponsor":392,"locationsCount":78},"100624309","screening-and-staging-of-benign-vs-malignant-pelvic-abnormalities-100624309","NCT07407959","Screening and Staging of Benign vs Malignant Pelvic Abnormalities","Clinical Evidence Generation of AI Enabled Fast, Accurate and Precise Screening and Staging of Benign vs Malignant Pelvic Abnormalities","Inclusion Criteria:\n\n* Patient over the age of 18\n* For prostate group, any patient referred for prostate MR for screening purposes with no prior prostate related treatment or prior biopsy\n* For endometriosis group, any patient referred for possible endometriosis evaluation (pre-surgical)\n\nExclusion Criteria:\n\n* Individuals unable to undergo MRI imaging (MR-conditional or MR-nonconditional devices which would need additional procedures\u002Fconditions for scanning, pregnant people, individuals with implanted metal, etc.)\n* Patient under the age of 18\n* Patient who is unable to consent",{"count":288,"type":20},"This study evaluates whether newly developed non-FDA approved image processing techniques \\[Adaptive Image Reconstruction (AIR Recon) Deep Learning (DL) and Sonic DL\\] can provide improved quality and decreased time compared to current scanning techniques.",[29,203],"2026-02-12",{"date":387,"type":43},"2026-02-17",{"date":389,"type":43},"2025-09-04",{"date":391,"type":20},"2028-09-30",{"name":77,"class":49},{"id":394,"slug":395,"hasResults":11,"nctId":396,"briefTitle":397,"officialTitle":398,"acronym":4,"eligibilityCriteria":399,"healthyVolunteers":11,"sex":126,"minAge":17,"maxAge":4,"enrollmentInfo":400,"targetDuration":4,"studyType":21,"phases":402,"briefSummary":403,"conditions":404,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":417,"lastUpdatePostDateStruct":418,"startDateStruct":420,"completionDateStruct":422,"leadSponsor":424,"locationsCount":78},"100581853","an-automated-personalized-physical-activity-intervention-to-improve-immune-function-and-clinical-outcomes-in-stage-ii-iv-ovarian-primary-peritoneal-or-fallopian-tube-cancer-and-newly-diagnosed-endometrial-cancer-life-on-the-go-3-study-100581853","NCT06855706","An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in Stage II-IV Ovarian, Primary Peritoneal or Fallopian Tube Cancer and Newly Diagnosed Endometrial Cancer, Life on the Go 3 Study","Life on the Go 3: A Randomized Controlled Trial of Automated, Personalized Physical Activity Intervention Using Wearable Devices to Improve Immune Function and Clinical Outcomes in Ovarian and Endometrial Cancer Patients","Inclusion Criteria:\n\n* Age ≥ 18 years old on day of signing informed consent\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2\n* Participant must satisfy one of the following conditions:\n\n  * Have a clinically suspected or confirmed diagnosis of stage II-IV ovarian, primary peritoneal, or fallopian tube cancer by clinical presentation and elevated CA-125 and may be awaiting staging surgery or tumor tissue biopsy followed by neoadjuvant chemotherapy. Inclusion of clinically suspected ovarian cancer cases is because we want to capture data starting from the earliest point of the diagnostic pathway and before definitive staging surgery. This allows us to assess the impact of physical activity and the feasibility of wearable device monitoring as patients transition into neoadjuvant chemotherapy and potential surgery\n  * Have recurrent ovarian, primary peritoneal, or fallopian tube cancer at any time point of their recurrence, if they meet eligibility criteria (any histology accepted). Inclusion of recurrent ovarian cancer cases is because ovarian cancer often recurs, and understanding physical activity patterns and interventions in patients experiencing recurrence is critical for comprehensive insights. This ensures the study includes the continuum of disease management beyond initial diagnosis\n  * Have pre-operative biopsy-proven endometrial cancer (endometrioid, serous, mucinous, or clear cell, poorly differentiated) with plans for surgical resection using a minimally invasive approach or medical management with chemotherapy combination, hormonal treatment or radiation. Inclusion of biopsy-proven endometrial cancer cases but not clinically suspected or recurrent cases is because we are focusing on confirmed, newly diagnosed patients who will undergo surgical resection or medical management\n* willing to wear the activity tracking device for at least 70% of their waking hours each day (11 hours\u002Fday) throughout the 6-month study period\n* under the care of Roswell Park Comprehensive Cancer Center during the study period, which includes one or more of the following:\n\n  * Receiving cancer treatment at Roswell Park Comprehensive Cancer Center\n  * Undergoing surgery at Roswell Park Comprehensive Cancer Center\n  * Participating in surveillance visits at Roswell Park Comprehensive Cancer Center\n  * Receiving adjuvant treatment at an outside facility but returning to Roswell Park Comprehensive Cancer Center for periodic consultation visits and agreeing to comply with all study procedures, including data sharing from external providers\n* willing to participate in questionnaires and blood and stool collection throughout the study for translational research purposes\n* Participant must understand the investigational nature of this study and sign an independent ethics committee\u002Finstitutional review board approved written informed consent form prior to receiving any study related procedure\n* Have a smartphone with daily internet access that is compatible with the wearable devices and applications used in the study (e.g., Fitbit Sense 2 and CGM applications)\n\n  * NOTE: Patients who are already achieving or exceeding the goal of 150 minutes of physical activity per week are eligible for this study. This inclusion is intentional, as the study aims to evaluate the full spectrum of physical activity levels-both baseline activity and changes over time-and their relationship with clinical outcomes, metabolic measures (e.g., glucose levels), inflammation, and physical function\n\nExclusion Criteria:\n\n* serious psychiatric illness that is not currently stabilized, including but not limited to:\n\n  * Schizophrenia or other psychotic disorders\n  * Bipolar disorder\n  * Sever major depressive disorder\n  * Severe personality disorders diagnosed by a qualified mental health professional\n  * Recent suicide attempt or psychiatric hospitalization within the previous 12 months\n* Life expectancy of less than 12 months, as determined by the Investigator based on clinical judgment and available prognostic tools\n* history of other invasive malignancies within the last two years, except for:\n\n  * Non-melanoma skin cancer\n  * In situ cervical cancer\n* resting heart rate greater than 120 beats per minute after 10 minutes of seated rest, confirmed on two separate measurements\n* systolic blood pressure greater than 180 mmHg or diastolic blood pressure greater than 100 mmHg, measured after 10 minutes of seated rest, confirmed on two separate measurements\n* Unstable angina or myocardial infarction within the past 3 months.\n\n  * Unstable Angina: Chest pain at rest or chest pain of increasing frequency, severity, or duration that requires medical attention\n  * Myocardial Infarction: Heart attack diagnosed by a medical professional\n* Pregnant or nursing participants will be excluded, as confirmed via urine test during screening procedures.\n* unwilling or unable to follow the protocol requirements, including but not limited to:\n\n  * Cognitive impairment that affects the ability to provide informed consent or comply with study procedures\n  * Language barriers without access to adequate translation services\n  * Lack of access to necessary technology (e.g., smartphones compatible with study devices)\n  * Other factors that would prevent adherence to study protocols\n* Any condition which, in the Investigator's opinion, makes the patient unsuitable for participation in the study or may interfere with the patient's ability to comply with the study requirements or the safety of the patient. Conditions may include, but are not limited to:\n\n  * Severe pulmonary disease\n  * Uncontrolled metabolic disorders\n  * Other significant medical conditions that pose a risk during increased physical activity\n* Participants who do not provide a valid cell phone number or do not consent to receive SMS messages from Fitabase for motivational and compliance monitoring purposes will be excluded from the study.",{"count":401,"type":20},120,[62],"This clinical trial compares the effect of an automated personalized physical activity intervention supported by wearable technology to standard of care on physical activity levels and quality of life in patients with stage II- IV ovarian, primary peritoneal, fallopian tube cancer or endometrial cancer that is newly diagnosed. Physical activity is a modifiable risk factor for the prevention and treatment of many diseases. In fact, increased levels of physical activity have been shown to decrease the risk of some cancers as well as increase overall survival in some cancers. Currently, standard of care guidelines include participation in at least 150 minutes of moderate exercise weekly. An automated personalized physical activity intervention may increase physical activity, enhance quality of life, and improve physical function and daily living activities compared to standard recommendations in patients with stage II-IV ovarian, primary peritoneal, fallopian tube or newly diagnosed endometrial cancer. This trial also evaluates the impact of physical activity on the gut microbiome and immune function. The microbiome is the collection of tiny organisms, like bacteria, that live in and on the body, especially places like the gut. These microorganisms play an important role in health. Information gathered from this study may help understand how the gut microbiome and physical activity influences the immune system in patients with stage II-IV ovarian, primary peritoneal, fallopian tube or newly diagnosed endometrial cancer.",[29,405,406,407,408,409,410,411,412,413,414,415,416],"Recurrent Fallopian Tube Carcinoma","Recurrent Ovarian Carcinoma","Recurrent Primary Peritoneal Carcinoma","Stage II Fallopian Tube Cancer AJCC v8","Stage II Ovarian Cancer AJCC v8","Stage II Primary Peritoneal Cancer AJCC v8","Stage III Fallopian Tube Cancer AJCC v8","Stage III Ovarian Cancer AJCC v8","Stage III Primary Peritoneal Cancer AJCC v8","Stage IV Fallopian Tube Cancer AJCC v8","Stage IV Ovarian Cancer AJCC v8","Stage IV Primary Peritoneal Cancer AJCC v8","2026-01-02",{"date":419,"type":43},"2026-01-06",{"date":421,"type":43},"2025-06-04",{"date":423,"type":20},"2028-04-30",{"name":425,"class":49},"Roswell Park Cancer Institute",{"id":427,"slug":428,"hasResults":11,"nctId":429,"briefTitle":430,"officialTitle":431,"acronym":4,"eligibilityCriteria":432,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":433,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":435,"conditions":436,"keywords":440,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":443,"lastUpdatePostDateStruct":444,"startDateStruct":446,"completionDateStruct":448,"leadSponsor":450,"locationsCount":98},"100613529","contribution-of-oncovascular-surgery-in-the-treatment-of-gynecological-advanced-malignant-diseases-100613529","NCT07267780","Contribution of Oncovascular Surgery in the Treatment of Gynecological Advanced Malignant Diseases.","The Contribution of Oncovascular Surgery in the Treatment of Gynecological Advanced Malignant Diseases: a Prospective and Retrospective Multicenter Study","Inclusion Criteria:\n\n\\- Retrospective Arm:\n\n1. Diagnosis of advanced or recurrent gynecologic cancer with vascular involvement requiring resection and\u002For reconstruction of major blood vessels, including:\n\n   * Ovarian carcinoma\n   * Cervical carcinoma\n   * Endometrial carcinoma\n   * Vulvar carcinoma\n   * Uterine or other types of sarcomas with vascular involvement\n2. Documented major vascular invasion, confirmed by preoperative imaging or intraoperative description.\n3. Patients who underwent onco-vascular surgery for advanced or recurrent gynecologic cancers between January 1, 2017, and August 31, 2025.\n4. Data Protection Impact Assessment (DPIA) approved for the management of retrospective data. (Deceased or untraceable patients will also be included to avoid selection bias, in accordance with Article 110 bis, paragraph 4 of the Italian Privacy Code. A DPIA will be produced and published on the Sponsor's website before study initiation, and patients who explicitly objected before death will not be included.)\n\nProspective Arm:\n\n1. Age ≥18 years\n2. Patients eligible for onco-vascular surgery for advanced or recurrent gynecologic cancers with vascular involvement, including:\n\n   * Ovarian carcinoma\n   * Cervical carcinoma\n   * Endometrial carcinoma\n   * Vulvar carcinoma\n   * Uterine or other types of sarcomas\n3. Documented major vascular invasion, confirmed by preoperative imaging or intraoperative description.\n4. Signed informed consent.\n\nExclusion Criteria:\n\n1. Patients younger than 18 years of age\n2. Patients with early-stage gynecologic cancers not eligible for onco-vascular surgery\n3. Patients undergoing vascular resection due to accidental injury of blood vessels not directly related to tumor infiltration.\n4. Patients who have previously undergone vascular surgery for reasons unrelated to the study, to avoid data overlap.",{"count":434,"type":20},130,"Multicenter ambispective observational study (prospective\u002Fretrospective)",[200,65,29,437,438,439],"Vulvar Carcinoma","Uterine Sarcoma","Gynecologic Tumor",[441,442],"Advanced or recurrent gynecologic tumor","Vascular infiltration","2025-11-25",{"date":445,"type":43},"2025-12-05",{"date":447,"type":20},"2025-12",{"date":449,"type":20},"2035-12",{"name":451,"class":49},"National Cancer Institute, Naples",{"id":453,"slug":454,"hasResults":11,"nctId":455,"briefTitle":456,"officialTitle":456,"acronym":457,"eligibilityCriteria":458,"healthyVolunteers":11,"sex":126,"minAge":17,"maxAge":4,"enrollmentInfo":459,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":461,"conditions":462,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":474,"lastUpdatePostDateStruct":475,"startDateStruct":477,"completionDateStruct":479,"leadSponsor":481,"locationsCount":483},"100443825","oracle-observation-of-residual-cancer-with-liquid-biopsy-evaluation-100443825","NCT05059444","ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation","ORACLE","Inclusion Criteria:\n\n* Age \\> 18 years old AND\n* Initial treatment is given with curative\u002Fradical intent AND\n* Are planning to undergo regular follow-up and monitoring for cancer recurrence per standard of care at the enrolling site AND\n* Provided written informed consent to participate in the study AND\n* Are willing to have de-identified clinical data shared with investigators at regular intervals as outlined in the study protocol and informed consent AND\n* Are willing to provide blood samples at enrollment and at subsequent clinical visits coinciding with standard of care follow-up, for up to 5 years as outlined in the study protocol and informed consent AND\n* Have at least one Landmark blood sample\n\nHave a histologically confirmed Index Cancer that qualifies for inclusion, defined as:\n\nPrimary Study Cohorts\n\n* Cohort 1: Cohort 1: Muscle invasive carcinoma of the bladder, ureter, or renal pelvis (stage II-III),\n* Cohort 2: Cohort 2: Non-small cell lung cancer (stage IB-III):\n\nCohort 2A: Resectable OR Cohort 2B: Unresectable,\n\n* Cohort 3: Invasive breast carcinoma with hormone receptor (e.g. estrogen receptor (ER) and progesterone receptor (PR) expression) and human epidermal growth factor receptor 2 (HER2) status known and one the following:\n\nCohort 3A: High-risk2 HER2+ breast cancer (any ER, PR status allowed) OR Cohort 3B: High-risk2 triple negative breast cancer (TNBC) OR Cohort 3C: High-risk3 HR-positive\u002FHER2-negative invasive breast carcinoma,\n\n* Cohort 4: Stage IIB-III cutaneous melanoma or limited (resectable) stage IV melanoma treated with curative intent,\n* Cohort 5: Esophageal or gastroesophageal junction carcinoma (stage II-III),\n* Cohort 6: Gastric adenocarcinoma (stage II-III),\n* Cohort 7: Pancreatic adenocarcinoma that is has been surgically resected or is eligible for surgical resection,\n* Cohort 8: Invasive squamous cell carcinoma of the head and neck (Includes stage I-IVB oral cavity, oropharynx, hypopharynx, larynx, nasopharynx, nasal cavity, and paranasal sinus cancers),\n* Cohort 9: High-risk epithelial ovarian or Fallopian tube carcinoma (Defined as FIGO stage IC-III or stage IA-IB that has high grade or clear cell histology),\n* Cohort 10: High-risk endometrial carcinoma (Defined as 2023 FIGO Stage II-III),\n* Cohort 11: High-risk renal cell carcinoma (Defined as high grade (grade 3-4) stage II, stage III or limited (resectable) stage IV treated with curative intent)\n\nExploratory Cohort\n\n* Cohort 12: Pathologically confirmed adenocarcinoma of the rectum (located up to 15 cm from the anal verge) that is undergoing or underwent a preoperative chemotherapy- or immunotherapy- containing regimen\n\nExclusion Criteria:\n\n* History of allogeneic organ or tissue transplant\n* Index cancer has predominantly neuroendocrine histology\n* History of another primary cancer diagnosed within 3 years of enrollment, with the exception that in situ cancers, non-melanoma skin carcinomas, localized low- or intermediate risk prostate cancers, and stage I papillary thyroid carcinoma, and participants with bilateral\u002Fmultifocal tumors within the same organ (for example, bilateral breast cancer) are allowed if diagnosed within 3 years of enrollment\n* Known distant metastasis at time of enrollment (with the exception of participants with limited\u002Fresectable stage IV cutaneous melanoma or RCC)",{"count":460,"type":20},2020,"The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinical outcomes in order to demonstrate clinical validity for recurrence detection and explore its value in a healthcare environment subject to cost containment.",[183,463,464,465,466,467,468,187,469,470,471,472,186,29,204,473],"Ureter Carcinoma","Renal Pelvis Carcinoma","Non-small Cell Lung Cancer","Invasive Breast Carcinoma","Cutaneous Melanoma","Esophageal Carcinoma","Gastric Adenocarcinoma","Pancreatic Adenocarcinoma","Squamous Cell Carcinoma of the Head and Neck","Epithelial Ovarian Carcinoma","Rectal Adenocarcinoma","2025-08-18",{"date":476,"type":43},"2025-08-22",{"date":478,"type":43},"2021-09-07",{"date":480,"type":20},"2029-08",{"name":482,"class":166},"Guardant Health, Inc.",57,{"id":485,"slug":486,"hasResults":11,"nctId":487,"briefTitle":488,"officialTitle":488,"acronym":4,"eligibilityCriteria":489,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":490,"targetDuration":4,"studyType":21,"phases":492,"briefSummary":493,"conditions":494,"keywords":499,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":502,"lastUpdatePostDateStruct":503,"startDateStruct":505,"completionDateStruct":507,"leadSponsor":508,"locationsCount":98},"100426946","concurrent-laparoscopic-hysterectomy-and-weight-loss-surgery-in-obese-patients-with-endometrial-carcinoma-or-endometrial-intraepithelial-neoplasia-100426946","NCT04839614","Concurrent Laparoscopic Hysterectomy and Weight Loss Surgery in Obese Patients With Endometrial Carcinoma or Endometrial Intraepithelial Neoplasia","Inclusion Criteria:\n\n* Female adults at least 18 years of age\n* A BMI of 35-39.99 and 1 or more severe obesity-related co-morbidities\n\n  --including T2D,112 hypertension, hyperlipidemia, obstructive sleep apnea (OSA), obesity-hypoventilation syndrome (OHS), Pickwickian syndrome (a combination of OSA and OHS), nonalcoholic 4 fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH), pseudotumor cerebri, gastroesophageal reflux disease (GERD), asthma, venous stasis disease, severe urinary incontinence, debilitating arthritis, or considerably impaired quality of life) OR a BMI ≥ 40\n* Tissue diagnosis (usually endometrial biopsy) of grade 1 endometrial carcinoma or EIN.\n\nExclusion Criteria:\n\n* Younger than 18 years old\n* BMI \\\u003C 35\n* Without a tissue diagnosis, or with a grade 2 or greater endometrial cancer tissue diagnosis\n* Pregnant participants will be excluded from this study.\n* Patients with contraindications to bariatric surgery will also be excluded.\n\n  --This includes active smokers, prior bariatric surgery, active substance abuse, recent suicide attempt, bulimia nervosa, large abdominal hernias, or poorly controlled psychiatric illness\n* include inability to read an English informed consent form, and unwillingness to provide informed consent.",{"count":491,"type":20},30,[62],"To assess the feasibility of an expedited referral process for the obese endometrial cancer or EIN patient from her gynecologic oncologist to the Brigham Center for Metabolic and Bariatric Surgery (CMBS) in order to undergo concurrent weight loss surgery and hysterectomy within 8 weeks of first appointment with a gynecologic oncologist (or 12 weeks for EIN patients).",[29,495,496,497,498],"Obesity","EIN","Endometrial Intraepithelial Neoplasia","Endometrial Cancer Stage I",[29,495,496,497,498,500,501],"Weight Loss Surgery","Bariatric Surgery","2025-08-04",{"date":504,"type":43},"2025-08-07",{"date":506,"type":43},"2021-08-01",{"date":253,"type":20},{"name":509,"class":49},"Dana-Farber Cancer Institute",{"id":511,"slug":512,"hasResults":11,"nctId":513,"briefTitle":514,"officialTitle":515,"acronym":516,"eligibilityCriteria":517,"healthyVolunteers":11,"sex":126,"minAge":17,"maxAge":4,"enrollmentInfo":518,"targetDuration":4,"studyType":21,"phases":520,"briefSummary":521,"conditions":522,"keywords":552,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":583,"lastUpdatePostDateStruct":584,"startDateStruct":586,"completionDateStruct":588,"leadSponsor":590,"locationsCount":176},"100445919","phase-1-a-beta-only-il-2-immunotherapy-study-100445919","NCT05086692","A Beta-only IL-2 ImmunoTherapY Study","A Phase 1\u002F2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors","ABILITY-1","Key Inclusion Criteria:\n\n1. Aged at least 18 years (inclusive at the time of informed consent).\n2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1.\n3. Must be able and willing to provide written informed consent prior to start of any study procedures and assessments and must be willing to comply with all study procedures.\n4. Histologically or cytologically confirmed locally advanced or metastatic solid tumor (see tumor types listed under conditions)\n5. Demonstrated adequate organ function\n6. Measurable disease as per Response Evaluation Criteria in Solid Tumors, (RECIST v1.1) and documented by CT and\u002For MRI.\n7. Life expectancy of ≥ 12 weeks.\n8. Women of childbearing potential (WOCBP) must have a negative pregnancy test at screening and within 72 hours before the first dose of study drug(s). Women must not be breastfeeding.\n9. Agree to use highly effective contraception methods. WOCBP must agree to use highly effective birth control.\n\nKey Exclusion Criteria:\n\n1. Last administration of prior antitumor therapy:\n\n   * Prior systemic anti-cancer therapy including investigational agents within 4 weeks (could consider shorter interval for kinase inhibitors or other short half-life drugs) prior to start of treatment.\n   * Prior radiotherapy within 2 weeks prior to start of treatment or has had a history of radiation pneumonitis. A 1-week washout is required for palliative radiation (\\\u003C2 weeks of radiotherapy) to non-CNS disease.\n   * Radiation therapy to the lung that is \\> 30Gy within 6 months prior to start of treatment.\n   * Currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to start of treatment. Concomitant participation in an observational study must be discussed on a case-by-case basis with the MM for approval.\n2. Has known active CNS metastases and\u002For carcinomatous meningitis. Patients with previously treated brain metastases may participate provided they are radiologically stable, i.e., without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to start of treatment, subject to discussion with MM.\n3. Active malignancy (other than the disease under treatment in the study) within the previous 3 years except for curable cancers.\n4. Condition requiring long-term systemic treatment with either corticosteroids \\> 10 mg daily prednisone equivalent or any other form of immunosuppressive therapy within 7 days prior to start of treatment.\n5. Clinically significant active, known or suspected autoimmune disease, or diseases that can be exacerbated with immunotherapy.\n6. Severe pulmonary, cardiac or other systemic disease.\n7. Known hepatitis B or C virus infection.\n8. Females who are pregnant or lactating or planning to become pregnant during the study.\n9. Has had an allogeneic tissue\u002Fsolid organ transplant.\n10. Active infection requiring systemic therapy.\n11. Any medical, emotional or psychiatric condition that interfere with the patient's ability to adhere to the protocol\n12. Any other underlying medical conditions that, in the Investigator's opinion, will make the administration of study drug(s) unsafe or obscure the interpretation of toxicity determination or adverse events.\n13. Known severe hypersensitivity to any component of study drug(s).\n14. Inability to comply with study and follow up procedures as judged by the Investigator.",{"count":519,"type":20},115,[130,131],"This is a Phase 1\u002F2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.",[523,524,525,526,527,528,529,530,531,181,532,197,533,534,535,536,29,136,537,538,539,472,540,541,542,543,467,544,545,342,546,547,548,549,550,551,26],"Advanced Solid Tumor","Unresectable Solid Tumor","Clear Cell Renal Cell Carcinoma","Triple Negative Breast Cancer","Non-Small Cell Lung Cancer Squamous","Non-Small Cell Lung Cancer Non-squamous","Colorectal Cancer (MSI-H)","Gastric Cancer","Cervical Cancer","Bladder Cancer","Squamous Cell Carcinoma of Head and Neck","Cutaneous Squamous Cell Carcinoma","Pleural Mesothelioma","Esophageal Cancer","Solid Tumor, Adult","MSI-H Solid Malignant Tumor","Cancer With A High Tumor Mutational Burden","Primary Peritoneal Cancer","Gastroesophageal Junction (GEJ) Cancer","Acral Melanoma","Mucosal Melanoma","DMMR Solid Malignant Tumor","Fallopian Tube Cancer","MSI-H Cancer","DMMR Cancer","Pancreas Adenocarcinoma (MSI-H)","Skin Cancer","Viral Cancer","Cervical Cancers",[553,554,555,556,557,558,559,560,561,562,563,564,565,566,567,568,569,570,571,572,573,574,575,576,577,578,579,140,580,581,582],"IL-2","IL2","Interleukin-2","cancer","metastatic","ccRCC","TNBC","NSCLC","CRC","GEJ","intrahepatic","extrahepatic","MCC","SCCHN","CSCC","Gastroesophageal Junction","advanced","unresectable","MSI-H","dMMR","Microsatellite Instability-High","Mismatch Repair Deficient","PD-1","immunotherapy","anti-PD-1","BCC","RCC","Tumor Mutation Burden High","TMB-H","PDAC","2025-07-03",{"date":585,"type":43},"2025-07-09",{"date":587,"type":43},"2021-08-27",{"date":589,"type":20},"2026-12-30",{"name":591,"class":166},"Medicenna Therapeutics, Inc.",{"id":593,"slug":594,"hasResults":11,"nctId":595,"briefTitle":596,"officialTitle":597,"acronym":4,"eligibilityCriteria":598,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":599,"targetDuration":601,"studyType":87,"phases":4,"briefSummary":602,"conditions":603,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":421,"lastUpdatePostDateStruct":606,"startDateStruct":608,"completionDateStruct":610,"leadSponsor":612,"locationsCount":614},"100594142","patient-journey-in-advanced-gynecologic-cancers-100594142","NCT07015593","Patient Journey in Advanced Gynecologic Cancers","Patient Journey in Conventional Therapy for Primarily Treated Advanced Gynecologic Cancers in China","Inclusion Criteria:\n\n* Age 18 or older\n* Newly diagnosed stage III or IV CC or EC\n* Completed their initial conventional therapies which must include at least chemotherapy, radiotherapy or a combination between Dec. 2022 to Dec. 2024 and the therapies were within 6 months after diagnosis.\n* Told by their physician that their disease is stable.\n* Patients must have informed consent form (ICF) signed for the study.\n\nExclusion Criteria:\n\n* Previously treated with targeted biologic therapy anti-PD-1, anti-PD-L1, or anti PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor.\n* Previously participated in or participating in a clinical trial.\n* Patients who received another line of therapy after initial therapy.\n* Unable or unwilling to provide informed consent.\n* Not fluent in local language.\n* Indicates or exhibits hearing difficulties, which would make a conversation challenging.",{"count":600,"type":20},780,"1 Day","This is a mixed-methods survey study including a 2-phased sequential-explanatory design. This study is to understand the patient journey in conventional therapy for newly diagnosed stage III or IV CC or EC in China, including ①patients' treatment decision making factors and treatment experiences and ② patients' unmet needs during post-treatment surveillance.",[604,605,29],"Genital Neoplasms, Female","Uterine Cervical Neoplasms",{"date":607,"type":43},"2025-06-11",{"date":609,"type":20},"2025-07-01",{"date":611,"type":20},"2026-11-30",{"name":613,"class":49},"Tongji Hospital",4,{"id":616,"slug":617,"hasResults":11,"nctId":618,"briefTitle":619,"officialTitle":620,"acronym":621,"eligibilityCriteria":622,"healthyVolunteers":11,"sex":126,"minAge":17,"maxAge":4,"enrollmentInfo":623,"targetDuration":4,"studyType":21,"phases":625,"briefSummary":627,"conditions":628,"keywords":635,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":421,"lastUpdatePostDateStruct":636,"startDateStruct":638,"completionDateStruct":640,"leadSponsor":642,"locationsCount":644},"100445254","phase-3-study-comparing-the-standard-administration-of-io-versus-the-same-io-administered-each-3-months-in-patients-in-response-after-6-months-of-standard-io-100445254","NCT05078047","Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO","Randomized Phase III Trial of Standard Immunotherapy (IO) by Checkpoint Inhibitors, Versus Reduced Dose Intensity of IO in Patients With Locally Advanced or Metastatic Cancer in Response After 6 Months of Standard IO","MOIO","Inclusion Criteria:\n\n1. Patients must have signed a written informed consent form prior to any trial specific procedures.\n2. Patient aged ≥18 years old.\n3. Metastatic disease (or locally advanced disease not suitable for local treatment) of initial tumor histologically confirmed including: lung cancer, renal cell cancer, head and neck cancer, urothelial carcinoma, triple negative breast cancer, Merkel cancer, hepatocellular carcinoma, melanoma, colorectal carcinoma with microsatellite instability \\[MSI\\], esophageal squamous cell carcinoma, endometrial carcinoma,cervical cancer, gastric\u002Fgastro-oesophageal junction adenocarcinoma, basal cell carcinoma or squamous skin carcinoma.\n4. Patients in partial or complete response after 6 months of standard immunotherapy (whatever the line of therapy) according to the RECIST or PERCIST v1.0 criteria (confirmed by local radiological assessment).\n\n   For metastatic melanoma only patients in partial response. Patients with metastatic or advanced cancer treated by immunotherapy as maintenance therapy can be included without any lesion at IO initiation. In this case, response after 6 months of standard immunotherapy will be evaluated by the non-appearance of a new lesion.\n5. Eligible to maintain the same standard IO treatment.\n6. Patient with Eastern cooperative oncology group (ECOG) performance status ≤1.\n7. Patients with brain metastases are allowed, provided they are stable according to the following definitions: treated with surgery or stereotactic radiosurgery and without evidence of progression prior to randomization and have no evidence of new or enlarging brain metastases.\n8. Patients treated by IO previously combined with chemotherapy are allowed.\n9. Patients with Tyrosine Kinase Inhibitor (TKI)-IO or pemetrexed-IO or bevacizumab-IO are allowed.\n10. Evidence of post-menopausal status, or negative urinary or serum pregnancy test for pre-menopausal patients.\n11. Both sexually active women of childbearing potential and males (and their female partners) patients must agree to use adequate contraception method for the duration of the study treatment and after completing treatment according to the most recent version of the IO Summary of product characteristics (SmPC).\n12. Patient is willing and able to comply with the protocol for the duration of the trial including undergoing treatment and scheduled visits, and examinations including follow-up.\n13. Patient must be affiliated to a Social Security System.\n\nExclusion Criteria:\n\n1. Metastatic melanoma in complete response.\n2. Metastatic renal cell carcinoma with International Metastatic Renal Cell Carcinoma Database (IMDC) favourable-risk treated TKI\u002FIO combination.\n3. Hematologic malignancies (leukaemia, myeloma, lymphoma…)\n4. Active infection requiring systemic therapy.\n5. Patients enrolled in another therapeutic study within 30 days before the inclusion in and during MOIO study.\n6. Patient unable to comply with study obligations for geographic, social, or physical reasons, or who is unable to understand the purpose and procedures of the study.\n7. Person deprived of their liberty or under protective custody or guardianship.",{"count":624,"type":20},646,[626],"PHASE3","Immunotherapy (IO), such as treatment with anti-PD-1, PD-L1, or CTLA-4 inhibitors, is a rapidly expanding treatment for multiple metastatic cancers with improved survival for certain cancers. However, the optimal duration of immunotherapies is currently unknown. Our hypothesis is that a reduced dose intensity of IO could be as effective as the current standard treatment in term of prevention of the disease progression. If proved right, this study will have a positive medico-economic impact by reduction of the costs associated with the treatment and the toxicity, and an increase of the patients' quality of life.",[629,204,630,526,197,191,196,206,631,632,29,531,633,181,634],"Lung Cancer Metastatic","Head and Neck Cancer","Colorectal Carcinoma With Microsatellite Instability","Esophageal Squamous Cell Carcinoma","Gastric\u002FGastro-esophageal Junction\u002FEsophageal Adenocarcinoma","Squamous Skin Carcinoma",[297],{"date":637,"type":43},"2025-06-05",{"date":639,"type":43},"2022-03-08",{"date":641,"type":20},"2027-03-07",{"name":643,"class":49},"UNICANCER",40,{"id":646,"slug":647,"hasResults":11,"nctId":648,"briefTitle":649,"officialTitle":650,"acronym":651,"eligibilityCriteria":652,"healthyVolunteers":11,"sex":16,"minAge":653,"maxAge":4,"enrollmentInfo":654,"targetDuration":4,"studyType":21,"phases":656,"briefSummary":657,"conditions":658,"keywords":662,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":666,"lastUpdatePostDateStruct":667,"startDateStruct":669,"completionDateStruct":671,"leadSponsor":673,"locationsCount":675},"100554719","phase-2-first-line-carboplatin-and-paclitaxel-in-combination-with-pembrolizumab-followed-by-maintenance-pembrolizumab-with-or-without-nesuparib-in-patients-with-newly-diagnosed-advanced-or-recurrent-mmr-proficient-pmmr-endometrial-cancer-100554719","NCT06502743","First-line Carboplatin and Paclitaxel in Combination With Pembrolizumab, Followed by Maintenance Pembrolizumab With or Without Nesuparib, in Patients With Newly Diagnosed Advanced or Recurrent MMR-proficient (pMMR) Endometrial Cancer","Phase 2 Study of First-line Carboplatin and Paclitaxel in Combination With Pembrolizumab, Followed by Maintenance Pembrolizumab With or Without Nesuparib, in Patients With Newly Diagnosed Advanced or Recurrent MMR-proficient (pMMR) Endometrial Cancer","PENELOPE","Inclusion Criteria:\n\n1. Patient must be female ≥ 19 years of age\n2. Histologic confirmation of the original primary tumor is required. Patients with the following histologic types are eligible: Endometrioid adenocarcinoma, serous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, carcinosarcoma, adenocarcinoma not otherwise specified (N.O.S.).\n3. Measurable stage III, measurable stage IVA, stage IVB (with or without measurable disease) or recurrent (with or without measurable disease) endometrial cancer.\n4. MMR proficient confirmed by institutional (local) MMR IHC testing.\n5. Patient must provide the institutional (local) P53 IHC result.\n6. Prior Therapy;\n\n   * Naïve to first line systemic anti-cancer treatment. For patients with recurrent disease only, prior systemic anti-cancer treatment is allowed only if provided adjuvant chemotherapy was completed ≥ 12 months prior to randomization.\n\n     a. Note : For Part A(Safety lead in phase), patient who used Paclitaxel, Carboplatin and Pembrolizumab for first line systemic therapy can participate if they meet all of the following conditions. Patient must have had 6 cycles of chemotherapy; patient must have physician assessed stable disease (SD), partial response (PR), or complete response (CR) after 6 cycles of therapy and patient must be enrolled within 9 weeks of their last dose of chemotherapy (last dose is the day of the last infusion)\n   * Patients may have received prior radiation therapy for treatment of endometrial cancer. Prior radiation therapy may have included pelvic radiation therapy, extended field pelvic\u002Fpara-aortic radiation therapy, and\u002For intravaginal brachytherapy. All radiation therapy must be completed at least 4 weeks prior to randomization.\n   * Patients may have received prior hormonal therapy for treatment of endometrial cancer. All hormonal therapy must be discontinued at least three weeks prior to randomization.\n7. Archival tumor tissue available or a fresh biopsy must be obtained prior to randomization.\n8. Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2\n9. Have adequate organ function. Specimens must be collected within 7days prior to the start of study intervention.\n\n   \\- Hematology Absolute neutrophil count (ANC) ≥1,500\u002FμL without growth factor support within 2 weeks before screening test.\n\n   Platelet ≥100,000\u002FμL without transfusion within 2 weeks prior to screening test.\n\n   Hemoglobin ≥10.0 g\u002FdL without transfusion within 2 weeks prior to screening test.\n   * Kidney function Creatinine or measured or calculated creatinine clearance (GFR may also be used in place of creatinine or CrCl a) ≤1.5 × ULN or ≥30 mL\u002Fmin for subjects with creatinine levels \\>1.5 × institutional ULN.\n   * liver function Total bilirubin ≤1.5×ULN or direct bilirubin ≤ULN for subjects whose total bilirubin exceeds 1.5 times the normal value.\n\n   AST (SGOT) and ALT (SGPT) ≤3 × ULN (≤5 × ULN in subjects with liver metastases)\n   * Coagulation International normalized ratio (INR) or prothrombin time (PT) Activated partial thromboplastin time (aPTT) ≤1.5\n   * Thyroid function Thyroid stimulating hormone (TSH) within normal limits (WNL); In euthyroid subjects receiving thyroid replacement therapy, TSH \\\u003C ULN; If an abnormal TSH result is shown, free T4 is normal, and glandular function (euthyroid) is clinically normal, registration is possible.\n10. Patient has voluntarily agreed to participate by giving written informed consent\u002Fassent for the trial.\n11. Women of childbearing potential (WOCBP) must agree to use adequate contraception (hormonal method or abstinence, contraceptive procedure (IUD, Mirena, etc.)) from up to 14 days prior to randomization (for oral contraceptives), during treatment, and for 6 months after the last dose of Paclitaxel + Carboplatin, for 4 months after the last dose of Pembrolizumab, for 3 months after the last dose of Nesuparib, whichever occurs last.\n12. Should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately. Patients will be considered of nonreproductive potential if they are either:\n\n    * Postmenopausal (defined as at least 12 months with no menses without an alternative medical cause; in women \\\u003C45 years of age, a high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy. In the absence of 12 months of amenorrhea, a single FSH measurement is insufficient); OR\n    * Have a hysterectomy and\u002For bilateral oophorectomy, bilateral salpingectomy or bilateral tubal ligation\u002Focclusion, at least 6 weeks prior to randomization; OR Have a congenital or acquired condition that prevents childbearing.\n\nExclusion Criteria:\n\n1. Patient has undergone prior treatment with a known PARP inhibitor.\n2. Patient has a known hypersensitivity to nesuparib, pembrolizumab or combination cytotoxic chemotherapy components or excipients.\n3. MMR deficiency confirmed by institutional MMR IHC testing.\n4. Patients who are currently participating and receiving cancer-directed study therapy or have participated in a study of an investigational agent and received cancer-directed study therapy within 4 weeks prior to randomization.\n5. Patient has known active central nervous system (CNS) metastases and\u002For carcinomatous meningitis. Patients with treated brain metastases may be eligible if follow-up brain imaging after CNS directed therapy shows no evidence of progression, and they have been off steroids for at least 4 weeks prior to randomization and remain clinically stable.\n6. Patient has a known additional malignancy that progressed or required active treatment within the last 2 years. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy, or in situ cervical cancer.\n7. Patient has received a live vaccine or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed.\n8. Patient has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to randomization.\n\n   * Patients who have received steroids as CT scan contrast premedication may be enrolled.\n   * The use of inhaled or topical corticosteroids is allowed.\n   * The use of mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed.\n   * The use of physiologic doses of corticosteroids may be approved after consultation with the study chair.\n9. Patients who have a history of (non-infectious) pneumonitis that required steroids, or current pneumonitis.\n10. Patient with uncontrolled intercurrent illness including, but not limited to: ongoing or active infection (except for uncomplicated urinary tract infection), interstitial lung disease or active, noninfectious pneumonitis, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n11. Patient has a known history of human immunodeficiency virus (HIV) (HIV 1\u002F2 antibodies)\n12. History of Hepatitis B (defined as HBsAg reactive) or known active Hepatitis C virus (defined as detectable HCV RNA \\[qualitative\\]) infection. Note: Testing for Hepatitis B or C is not required unless mandated by local health authority.\n13. Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication.\n14. Patient has known history or current diagnosis of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).\n15. Patients with systemic autoimmune disease such as Systemic Lupus Erythematosus.\n16. Has not adequately recovered from major surgery or has ongoing surgical complications.\n17. Has a history or current evidence of any condition, therapy, or laboratory abnormality or other circumstance that might confound the results of the study, interfere with the participant's participation for the full duration of the study, such that it is not in the best interest of the participant to participate, in the opinion of the treating investigator.\n18. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n19. Is pregnant or breastfeeding or expecting to be pregnant or conceive children within the projected duration of the study, starting with the screening visit through 6 months after the last dose of Paclitaxel + Carboplatin, 4 months after the last dose of Pembrolizumab, 3 months after the last dose of Nesuparib, whichever occurs last.\n20. Has had an allogenic tissue\u002Fsolid organ transplant.","19 Years",{"count":655,"type":20},92,[131],"The goal of this study is listed below.\n\nPart A (Safety Run-in Phase) : To determine feasibility of pembrolizumab and nesuparib combination as maintenance therapy in patients with MMR-proficient advanced and recurrent endometrial cancer. Feasibility is defined as a dose-limiting toxicity (DLT) rate less than or equal to 33%.\n\nPart B (Randomization Phase)\n\n: To evaluate the efficacy of pembrolizumab and nesuparib combination\u002F pembrolizumab monotherapy as maintenance therapy in patients with MMR-proficient advanced stage and recurrent endometrial cancer. Efficacy will be assessed by investigator assessed progression free survival (PFS) as assessed by RECIST 1.1.",[26,659,29,660,661],"Recurrent Endometrial Carcinoma","Gynecologycal Cancer","Endometrial Neoplasms",[663,664,665],"Nesuparib","pMMR","MMR-proficient","2025-03-30",{"date":668,"type":43},"2025-04-03",{"date":670,"type":43},"2024-09-12",{"date":672,"type":20},"2027-12",{"name":674,"class":49},"Yonsei University",6,{"id":677,"slug":678,"hasResults":11,"nctId":679,"briefTitle":680,"officialTitle":680,"acronym":4,"eligibilityCriteria":681,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":682,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":684,"conditions":685,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":688,"lastUpdatePostDateStruct":689,"startDateStruct":691,"completionDateStruct":692,"leadSponsor":693,"locationsCount":78},"100564688","clinicopathological-analysis-of-endometrial-carcinoma-in-the-view-of-old-and-new-international-federation-of-gynecology-and-obestetrics-figo-100564688","NCT06632431","Clinicopathological Analysis of Endometrial Carcinoma in the View of Old and New International Federation of Gynecology and Obestetrics (FIGO)","Inclusion Criteria:\n\n\\- Patients diagnosed with endometrial cancer (EC) who underwent surgical staging (total hysterectomy and bilateral salpingo-oophorectomy) between January 1, 2018, and December 31, 2022 with available medical records since diagnosis and at least follow up 2 years and received adjuvant treatment and available histopathological slides and blocks.\n\nExclusion Criteria:\n\n\\- Patients who received neoadjuvant chemotherapy, had recurrent endometrial cancer, had multiple cancers, lacked histopathological slides and formalin-fixed paraffin-embedded blocks or lacked medical records were excluded",{"count":683,"type":20},110,"Assess the percentage change in stage and risk stratification for patients with endometrial cancer when transitioning from the FIGO 2009 endometrial staging system to the updated FIGO 2023 endometrial staging system.\n\nInvestigate the prognostic impact of the FIGO 2023 endometrial staging system on patient survival.\n\nEvaluate how the shift in stage classification between the FIGO 2009 and FIGO 2023 systems influences adjuvant management decisions for endometrial cancer.",[686,29,687],"Clinicopathological","Federation of Gynecology and Obestetrics","2024-10-10",{"date":690,"type":43},"2024-10-15",{"date":688,"type":43},{"date":276,"type":20},{"name":694,"class":49},"Assiut University",{"id":696,"slug":697,"hasResults":11,"nctId":698,"briefTitle":699,"officialTitle":700,"acronym":4,"eligibilityCriteria":701,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":702,"targetDuration":4,"studyType":21,"phases":704,"briefSummary":705,"conditions":706,"keywords":709,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":711,"lastUpdatePostDateStruct":712,"startDateStruct":713,"completionDateStruct":714,"leadSponsor":716,"locationsCount":78},"100547901","phase-2-camrelizumab-plus-fluzoparib-for-tp-53-mutated-endometrial-cancer-100547901","NCT06413992","Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer","Efficacy and Safety of Camrelizumab Plus Albumin-bound Paclitaxel\u002FCarboplatin Followed by Camrelizumab With or Without Fluzoparib Maintenance Therapy for TP-53 Mutated Recurrent or Metastatic Endometrial Cancer: A Phase II Trial","Inclusion Criteria:\n\n* Age ≥18\n* Eastern Cooperative Oncology Group (ECOG) Performance Status (ECOG): 0-2. Expected survival ≥ 6 months.\n* Patients with newly diagnosed International Federation of Gynecology and Obstetrics (FIGO) 2009 stage III-IV endometrial cancer or recurrent endometrial cancer after ≤ 1 line of platinum-based chemotherapy (including neoadjuvant, adjuvant, and concurrent chemotherapy). For patients who have failed platinum-based chemotherapy, a platinum-free interval of ≥ 12 months is required.\n* No restriction on pathological type, abnormal p53 expression indicated by immunohistochemistry, and confirmation of TP53 gene mutation by Sanger sequencing or next-generation sequencing (NGS).\n* No prior treatment with immune checkpoint blockade (ICB) or poly (ADP-ribose) polymerase inhibitor (PARPi).\n* Discontinuation of previous radiation therapy, chemotherapy, or hormone therapy for at least 4 weeks.\n* Adequate organ function as follows (no use of drugs containing blood components or corrective treatment with hematopoietic growth factors in the 7 days prior to randomization): Aspartate Aminotransferase (AST) and Alanine Transaminase (ALT) ≤ 2.5 times the upper limit of normal (≤ 5 times for patients with liver metastasis) and total bilirubin ≤ 1.5 times the upper limit of normal; serum creatinine ≤ 1.5 times the upper limit of normal; platelets ≥ 90,000 cells\u002Fmm3, hemoglobin ≥ 90 g\u002FL, and neutrophils ≥ 1,500\u002Fmm3.\n* Thyroid function prior to randomization: Thyroid-stimulating hormone (TSH) level ≤ 1 times the upper limit of normal, or if TSH is not within the normal range, free T4 ≤ 1 times the upper limit of normal.\n* Peripheral neuropathy grade \\\u003C 2 (Common Terminology Criteria for Adverse Events, CTCAE 5.0) before treatment.\n* Signed informed consent and ability to provide tumor tissue samples from initial diagnosis\u002Frecurrence for homologous recombination deficiency (HRD) testing.\n* Willingness to comply with clinic visits and follow-up.\n\nExclusion Criteria:\n\n* Currently participating in another clinical trial or within 4 weeks since completing another clinical trial.\n* Known allergy to any components of the investigational drug.\n* Previous treatment with immune checkpoint inhibitors, including but not limited to other anti-PD-1 and anti-PD-L1 antibodies.\n* Patients requiring the use of immunosuppressive medications.\n* Previous treatment with poly (ADP-ribose) polymerase inhibitors (PARPi).\n* Patients requiring systemic or absorbable topical corticosteroids at an immunosuppressive dose, or patients who have used prednisone or equivalent drugs at a dose \\>10 mg\u002Fday in the two weeks prior to taking the study drug.\n* Patients with any active autoimmune disease or a history of autoimmune diseases, including but not limited to active hepatitis, pneumonia, uveitis, colitis (inflammatory bowel disease), pituitary inflammation, vasculitis, nephritis, hyperthyroidism, and hypothyroidism, excluding resolved childhood asthma\u002Fatopic diseases and vitiligo. Patients with intermittent use of bronchodilators or other medical interventions for asthma should also be excluded.\n* Patients in the active infectious phase requiring antimicrobial treatment (e.g., antibiotics, antiviral drugs, antifungal drugs).\n* History of immunodeficiency, including human immunodeficiency virus (HIV) seropositivity or other acquired or congenital immunodeficiency diseases.\n* Uncontrolled clinically significant cardiac symptoms or diseases within the past year, including but not limited to New York Heart Association (NYHA) class II or higher heart failure, unstable angina, myocardial infarction within the past year, atrial fibrillation, clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention, PR interval \\>250 ms, or QTc ≥470 ms.\n* Arterial or venous thrombosis within the past 6 months.\n* Poorly controlled hypertension (systolic blood pressure ≥140 mmHg and\u002For diastolic blood pressure ≥90 mmHg) despite antihypertensive medication, proteinuria ≥(++) and 24-hour total urinary protein \\>1.0 g.\n* Coagulation abnormalities (international normalized ratio \\[INR\\] \\>2.0, prothrombin time \\[PT\\] \\>16s), bleeding tendency, or receiving thrombolytic or anticoagulant therapy.\n* Patients with other malignant tumors within the past 5 years, excluding basal cell carcinoma of the skin and squamous cell carcinoma of the skin.\n* Vaccination with live vaccines within 4 weeks prior to the first administration of the investigational drug. Note: Administration of inactivated seasonal influenza vaccines is allowed.\n* History of substance abuse with psychotropic drugs and unable to quit, or patients with psychiatric disorders.\n* The investigator believes that any other medical, psychiatric, or social factors may affect the rights, safety, ability to sign informed consent, patient's completion of the study, or interpretation of study results.",{"count":703,"type":20},117,[131],"This study is an open-label Phase II randomized controlled trial designed to evaluate the safety and efficacy of camrelizumab plus fluzoparib maintenance therapy in patients with recurrent or metastatic TP-53 mutated Endometrial Cancer. The study will also explore the prevalence of homologous recombination reficiency in Chinese patients with TP-53 mutated endometrial cancer and its therapeutic significance.",[29,707,708],"TP53 Mutation","Recurrent or Metastatic",[710],"TP53-mutated, Endometrial Carcinoma,Camrelizumab, Fluzoparib","2024-05-10",{"date":302,"type":43},{"date":711,"type":43},{"date":715,"type":20},"2027-06-01",{"name":717,"class":49},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",{"id":719,"slug":720,"hasResults":11,"nctId":721,"briefTitle":722,"officialTitle":723,"acronym":4,"eligibilityCriteria":724,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":725,"targetDuration":4,"studyType":21,"phases":727,"briefSummary":728,"conditions":729,"keywords":731,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":736,"lastUpdatePostDateStruct":737,"startDateStruct":739,"completionDateStruct":741,"leadSponsor":743,"locationsCount":78},"100417515","phase-2-niraparib-monotherapy-as-maintain-and-recurrent-treatment-of-endometrial-serous-carcinoma-100417515","NCT04716686","Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma","Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma: A Multi-center, Open-label, Prospective Clinical Study","Inclusion Criteria:\n\n* Women aged 18 or above\n* Histological confirmation of serous endometrial cancer or other types of endometrial cancer\n* FIGO stage III-IV\n* ESC Patients have received at least 6 cycles of first-line platinum containing chemotherapy after surgery and achieved CR, PR or SD; ESC patients have received platinum containing chemotherapy after the first relapse and achieved CR, PR or SD; these two types of patients are enrolled in cohort 1 and receive niraparib alone as maintenance therapy within 12 weeks after the last chemotherapy treatment.\n* ESC Patients have received \\>2 lines of platinum containing chemotherapy and relapsed; patients with other types of endometrial cancer have received \\>2 lines of platinum containing chemotherapy and have BRCA mutation or be defined as HRD positive; these 2 types of patients are enrolled in cohort 2 and receive niraparib monotherapy.\n* Radiotherapy or endocrine therapy history is allowed\n* Cohort 1 life expectancy\\> 6 months; Cohort 2 life expectancy\\> 4 months\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.\n* Patients agreed to provide blood samples for testing BRCA status and HRR mutations.\n* Patients agreed to provide formalin-fixed and paraffin-embedded tumor tissue samples for the detection of homologous recombination repair related genes (optional)\n* Laboratory criteria are as follows:\n* Neutrophil count ≥1500\u002FµL;Platelets ≥100,000\u002FµL;Hemoglobin ≥10g\u002FdL;Serum creatinine ≤1.5 times of the upper limit, or creatinine clearance ≥60mL\u002Fmin;Total bilirubin ≤1.5 times of the upper limit or direct bilirubin ≤1.0 times of the upper limit;AST and ALT ≤2.5 times of the upper limit, and must be ≤5 times of the upper limit of when liver metastasis exists.\n* Patients of reproductive potential must have a negative urinary or serum pregnancy test when done and promise to take effective contraceptive measuresduring the period of the study; Or without potential fertility, defined as:\n* Women who have undergone contraceptive operation(hysterectomy, bilateral oophorectomy or bilateral salpingectomy), or\n* over 60 years old, or≥40 and \\\u003C60 years of age, menopause for more than 12 months, and follicle-stimulating hormone test results are within the reference range of research institutions after menopause\n* Willingness to sign a written informed consent document and follow the plan\n* Any previous toxic and side effects of chemotherapy have recovered to ≤ CTCAE level 1 or baseline level, except for sensory neuropathy or hair loss with stable symptoms ≤ CTCAE level 2\n\nExclusion Criteria:\n\n* Allergic to active or inactive ingredients of ZL-2306 (nirapali) or drugs with similar chemical structure to ZL-2306 (nirapali)\n* Stage Ia(on invasion to myometrium)\n* Symptomatic, uncontrollable brain metastases or pial metastases(No imaging scan is required); patients with spinal cord compression can still be considered for enrollment if they have received targeted therapy and have evidence of clinically SD for at least 28 days (patients with controlled central nervous system metastasis must have received radiotherapy or chemotherapy at least 1 month before and with no new symptoms related to central nervous system lesions or symptoms suggesting disease progression)\n* Received surgery within 3 weeks before the start of the study, or any surgical effects that have not recovered.\n* Received palliative radiotherapy with \\>20% bone marrow 1 week before enrollment\n* Suffered from other aggressive cancers (except for fully treated basal or squamous cell skin cancer) within 2 years before enrollment\n* Previously or currently diagnosed as myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML)\n* Suffer from serious or uncontrollable diseases, including but not limited to:\n* Uncontrollable nausea and vomiting, inability to swallow drugs, any gastrointestinal diseases that may interfere with drug absorption and metabolism\n* Active viral infections such as human immunodeficiency virus, hepatitis B, hepatitis C, etc.\n* Uncontrolled grand mal seizures, unstable spinal cord compression, superior vena cava syndrome, or other mental disorders\n* Immune deficiency (except for splenectomy)\n* Any past or current disease, treatment or laboratory abnormality that may interfere with the results of the study, or be defined as not suitable for this study\n* Receive platelet or red blood cell transfusion within 4 weeks before the start of the study.\n* Pregnant or breastfeeding, or expect to become pregnant during the study.\n* Have received any PARP inhibitor treatment previously.",{"count":726,"type":20},83,[131],"Endometrial Serous carcinoma (ESC) has similar molecular characteristics to high-grade serous ovarian carcinoma (HGSOC) and basal cell-like breast cancer, such as similar Chromosomal instability, somatic copy number variation profiles and somatic mutations. The clinical treatment of ESC also refers to the treatment model of HGSOC. The PARP inhibitor niraparib used in this study, which was approved by FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy on March 27, 2017.\n\nThe homologous recombination related gene mutations in total endometrial cancer accounted for 22%. Homologous Recombination Repair Defect (HRD) +ARID1A accounted for 48%, and 53% of endometrial cancer cell lines were sensitive to PARP inhibitors. The incidence of HRD in endometrial cancer with high copy number (the pathological type is mainly ESC) is 50%, suggesting potential clinical applications of PARP inhibitors for the treatment of ESC.",[29,730],"Serous Carcinoma",[732,733,734,735],"Endometrial Serous carcinoma","maintenance therapy","recurrent therapy","PARP inhibitor","2024-01-04",{"date":738,"type":43},"2024-01-05",{"date":740,"type":43},"2021-06-01",{"date":742,"type":20},"2026-12-31",{"name":744,"class":49},"Shandong University"]